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Abstract 
 
My thesis research began with a project in which we were trying to determine the 
function of embryonic stem cell (ESC)-specific miRNAs.  Using luciferase constructs 
containing miRNA binding sites, luciferase expression was inhibited by endogenous 
miRNAs in ESCs, and by exogenous miRNAs in HeLa cells.  Inhibition of luciferase 
expression by miRNAs was inhibited in HeLa cells using 2’O-methyl-oligonucleotides.  
In ESCs, 2’O-methyl-oligonucleotides were only effective in partially inhibiting miR290 
function.  Partial inhibition of miR290 did not result in any obvious phenotypic changes 
in mESCs.  Later studies using 2’O-methyl-oligonucleotides in ESCs were also 
unsuccessful.  The function of ESC-specific miRNAs has since been studied by re-
introducing miRNAs into Dicer -/- cells which cannot make miRNAs.  These studies 
have shown that ESC-specific miRNAs are involved in de novo DNA methylation, self-
renewal, and cell-cycle regulation. 
Newly diagnosed glioblastoma (GBM) patients rarely survive more than two 
years even after surgery, radiotherapy, and chemotherapy using temozolomide (TMZ) or 
1,3-bis(2-chloroethy)-1-nitrosourea (BCNU).  Eventual regrowth of the tumor indicates 
that some tumor cells are resistant to therapy.  GBM neurosphere-initiating cells (NICs) 
are thought to be similar to tumor-initiating cells in vivo, and will form invasive tumors in 
mice, making neurosphere cultures a good model system for studying GBMs.  To test 
whether GBM NICs were resistant to chemotherapy, we used a neurosphere formation 
assay to measure the number of proliferating NICs in the presence of TMZ or BCNU.  
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The concentrations of chemotherapy drugs required to inhibit neurosphere 
formation were much less than those required to inhibit bulk cell proliferation or to 
induce cell death in our neurosphere cultures. For some cultures, there was a robust 
recovery of neurosphere formation after chemotherapy treatment which appeared to be 
DNA damage independent.  Some of the cultures that showed significant recovery of 
neurosphere formation underwent reversible cell cycle arrest, possibly reducing 
chemotoxicity in these cultures.   Collectively, these results indicate that GBM 
neurosphere cultures can regrow after being treated with clinically relevant doses of 
chemotherapy drugs.   Chemotherapy-treated neurosphere cultures remained viable, and 
formed tumors when injected into mice.  Our experiments show that these in vitro assays 
may be useful in predicting in vivo responses to chemotherapeutic agents. 
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CHAPTER I: 
Introduction 
Glioblastoma 
 Glioblastomas (GBMs) are highly infiltrative and malignant intracranial tumors 
characterized by high rates of mobidity and mortality [1, 2].  GBMs are one of the most 
common brain tumors found in adults.   Approximately 18% of reported brain tumors are 
GBMs [3], with approximately five new cases a year per every 100,000 people [2].  Men 
are more susceptible to GBMs (57% of cases) compared with women (43% of cases).  
95% of GBMs occur in Caucasians, with only 5% being reported in African Americans 
[3]. 
 Patients who develop a GBM may encounter a variety of symptoms.  Many 
patients experience headaches, which are thought to be caused by increased intracranial 
pressure from tumor growth.  When severe, headaches can induce nausea and vomiting.  
Patients with GBMs may also have seizures, impaired vision, confusion, memory loss, 
and personality changes [2]. 
 Malignant gliomas are classified as Grade IV astrocytomas based on histologic 
features by the World Health Organization (WHO), and can be either primary or 
secondary.  Grade IV malignant gliomas are characterized by increased cellularity, 
nuclear atypia, increased mitotic activity, increased microvascular proliferation, and 
necrosis.  Primary GBMs are derived de novo whereas secondary GBMs are a result of 
additional transformations from lower grade astrocytomas over the course of several 
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years.  Although primary and secondary GBMs contain several differences in genetic and 
chromosomal abnormalities, they appear to be morphologically identical and respond 
similarly to conventional therapies.  Primary GBMs generally occur in patients older than 
50, whereas secondary GBMs occur in patients under 45 years of age who were 
originally diagnosed with a lower grade astrocytoma [1, 2].  Approximately 70% of 
Grade II gliomas transform into Grade III/IV malignant gliomas within 5-10 years of 
diagnosis [1].  Life expectancy after diagnosis of either a primary or secondary GBM is 
similar, with the median survival time after diagnosis for a malignant GBM being 
between 12-15 months [2].   
 The accumulation of several genetic or chromosomal aberrations as well as 
deregulation of growth factor signaling pathways are thought to contribute to GBM 
formation and progression.  Primary GBMs developing de novo with no previous 
symptoms contain a range of genetic abnormalities including MDM2 gene amplification 
(10%) [1, 2], MDM2 protein overexpression (>50%) or amplification (10%) [1, 2, 4], 
LOH 10q (70%) [1, 2], p16Ink4a/p14ARF loss (30%) [1, 2, 4, 5], PTEN mutations (40%) 
[1, 2], inactivation of the p53 pathway (67%) [1, 4], PI3K mutation or amplification 
(20%) [1, 2], Rb mutations (25%) [1, 2, 4], and upregulation of HEY1 [6].  In addition to 
genetic and chromosomal abnormalities, GBMs also contain a range of defects in growth 
factor signaling.  The most common abnormalities in growth factor signaling in primary 
GBMs are caused by EGFR amplification (40%) or overexpression (60%) [1, 2], EGFR 
mutations (25%) [1, 2], PDGFR amplification (10%), and VEGF overexpression [2].  
Other signaling pathways that may be affected in GBMs include sonic hedgehog, 
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wingless, Notch, CXCR4, BMPs, MAPK, AKT, and mTor [1, 2].  GBMs contain a wide 
variety of abnormalities that likely contribute to their resistance to therapy.  In addition to 
expressing a wide range of mutations and abnormalities, individual tumors contain 
heterogeneous populations of cells that may not respond similarly to any individual 
therapy. 
 The current standard therapy for patients diagnosed with GBM includes multiple 
rounds of surgery, radiotherapy, and chemotherapy [2, 7].  The objective of surgical 
resection is to remove as much of the tumor as possible.  Reducing tumor volume may 
alleviate some of the symptoms patients are experiencing, such as headaches from 
intracranial pressure.  Due to the invasive nature of GBMs, however, surgical resection 
only provides a temporary reduction in tumor volume because residual GBM cells that 
could not be surgically removed will contribute to regrowth of the tumor with time.  
Patients with GBMs frequently undergo several rounds of surgery after diagnosis, 
followed by radiotherapy.  Radiotherapy is an essential component of GBM therapy, but 
even in combination with surgical debulking, is not sufficient in killing all GBM cells in 
the brain [2, 8].  Radiotherapy in combination with surgery results in increased patient 
survival, from 3-4 months with surgery alone to 8-9 months with combined surgery and 
radiotherapy [9].  To more effectively treat GBMs, chemotherapy treatment is 
administered in addition to surgery and radiotherapy. 
 To be effective, chemotherapy drugs used to treat GBMs must have a low 
molecular weight, high lipid solubility, low ionization, and minimal protein binding 
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capability so that they can effectively cross the blood brain barrier.  These properties 
limit the number of compounds that can be used to treat GBMs, unless they are surgically 
implanted into the tumor bed.  Two chemotherapeutic compounds primarily used to treat 
GBMs in combination with surgery and radiotherapy are carmustine (BCNU) and 
temozolomide (TMZ) [10]. 
 Prior to the discovery of TMZ, BCNU had been the most effective 
chemotherapeutic agent used to treat GBMs over the past few decades.  BCNU only 
partially crosses the blood brain barrier, and has a short serum half-life of 15 minutes.  
For these reasons, BCNU is most effective when implanted into the tumor cavity 
following surgical resection.  For this purpose, BCNU was incorporated into 
biodegradable polymer wafers that can be implanted into tumor beds following tumor 
resection.  These wafers, patented as Gliadel, were FDA approved in 2003.  As the 
biodegradable wafer degrades, BCNU is slowly released [10].  Pharmacokinetic studies 
indicate that tissue exposure to BCNU incorporated into a polymer wafer is 4-1,200 times 
higher compared with intravenous administration.  A day after surgical implantation of a 
BCNU infused polymer disc into monkey brain, 7 mM BCNU was detected in coronal 
sections.  After 30 days, BCNU could still be detected at 1.2 mM [11].  Based on these 
results, Gliadel appears to effectively infiltrate tumor tissue with a slow and stable release 
of BCNU.  Although BCNU can now be effectively administered, one major advantage 
TMZ has over BCNU is that it can be administered orally [10]. 
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 When given orally, TMZ is 100% bioavailable, bypassing the need for 
intravenous injection or surgical implantation.  The half-life of TMZ in aqueous buffer at 
physiological pH is approximately 1.8 hours, which is significantly longer than the 15 
minute half-life of BCNU [8].  Following a single oral dose, TMZ plasma concentrations 
peaked at ~26 µM between 0.33 and 2 hours [12].  Another study found peak 
concentrations of TMZ in plasma and CSF to be 70 µM and 10 µM respectively [13].  
Using labeled TMZ and positron emission tomography (PET) neuroimaging, Rosso et al 
examined the tissue distribution of TMZ in live patients.  Using this approach, they 
calculated that TMZ reaches concentrations between 15-30 µM in glioma tumor tissue 
[14].    
 Based on increases in median survival time, two year survival rates, and 
decreased toxicity, TMZ is currently the most promising chemotherapeutic agent used to 
treat GBMs.  In a study of 573 patients, TMZ combined with radiotherapy resulted in a 
14.6 month median survival time, compared with 12.1 months with radiotherapy alone.  
The two year survival rate was only 10.4% for patients treated with radiotherapy alone.  
When TMZ was administered in addition to radiotherapy, two year survival rates 
increased to 26.5%.  In addition to increasing survival time and rates, TMZ is also 
advantageous because it is better tolerated by patients due to its manageable toxicity.  
The minimal toxicity of TMZ allows patients to finish treatments without serious adverse 
affects [15].  After several administrations of TMZ, levels of drug did not accumulate in 
plasma and were eliminated through urine [12].  TMZ can even be tolerated in long-term 
treatments.  A recent study documented the treatment of three patients treated with TMZ 
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for five, seven, and eight years.  Of particular interest is one patient who had been 
diagnosed with a Grade IV GBM.  After eight years of TMZ treatment in combination 
with two surgeries and radiotherapy, the patient was stable and had no significant toxic 
side effects, indicating that in some cases TMZ treatment can be tolerated long-term and 
can ward off disease progression [7].   
 BCNU and TMZ are alkylating agents.  The alkylation of DNA following 
treatment with these agents results in base-base mismatches, DNA-DNA and DNA-
protein crosslinks [8, 10].  Alkylated bases and base-base mismatches will trigger 
activation of the mismatch repair system (MMR).  Lesions caused by methylation of the 
O6 position of Guanine (O6-meG), which is considered to be the most toxic lesion 
induced by these chemotherapeutic agents, cannot be repaired by MMR mechanisms.  
The unrepaired O6-meG lesion will eventually lead to dsDNA breaks and cell death as a 
result of apoptosis or autophagy [8].  DNA crosslinks, more commonly associated with 
methylation of the N7 position of Guanine (N7-meG), can block replication and 
transcription and cause replication-mediated dsDNA breaks, which can also eventually 
result in apoptosis. 
 Expression of MGMT, sometimes referred to as O6-methylguanine-DNA-
methyltransferase AGT, is one of the biggest factors in determining patient responses to 
TMZ.  Unrepaired O6-meG lesions induced by TMZ result in cell death due to futile 
DNA repair, dsDNA crosslinks, and eventually apoptosis.  MGMT reverses this 
alkylation by removing the methyl group from guanine, and transferring it to an internal 
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cystine residue (Cys145), preventing DNA damage-induced apoptosis.  MGMT is 
considered a „suicide repair protein‟ because once MGMT transfers the methyl group to 
itself, it gets degraded, and new MGMT must be synthesized in order to continue DNA 
repair [8, 16-18].   In a study done in peripheral blood mononuclear cells, seven days of 
TMZ treatment resulted in a 72% reduction in MGMT activity, which remained reduced 
for seven days after treatment.  These results indicate that prolonged TMZ treatment can 
significantly deplete MGMT activity even after treatment has ended [19].  Based on this 
observation, treatment with TMZ for longer than five days would be more efficacious in 
cells with active MGMT. 
 MGMT gene activity can also be silenced by promoter methylation.  Methylation 
of the promoter of MGMT results in gene silencing, which has been associated with a 
favorable outcome in patients [18, 20, 21].  In one study, the average survival of patients 
with methylated MGMT promoter was 13.7 months, compared with only 2.5 months for 
patients with unmethylated MGMT promoter [20].  Hypermethylation of the MGMT 
gene is associated with long-term survival [22], but not necessarily with inhibited 
metastasis [23].   
 In patients with an unmethylated MGMT promoter, MGMT activity can be 
reduced using the inhibitor O6-benzylguanine (BG).  BG serves as a low molecular 
weight substrate for MGMT.  The benzyl group of BG binds to the active cystine residue 
of MGMT.  As MGMT is a „suicide‟ enzyme, it is depleted by BG, rather than by 
removing alkyl groups resulting from alkylating chemotherapy [24].  Combined therapy 
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with BG and TMZ has been proposed for MGMT expressing tumors that do not respond 
as efficiently to TMZ [25].  A phase II clinical trial using combined TMZ and BG 
therapy in TMZ resistant Grade III anaplastic astrocytomas and Grade IV glioblastomas 
was recently published.  The results of this study indicate that combined TMZ/BG 
therapy restored TMZ sensitivity in anaplastic astrocytomas, but not GBMs [26], 
indicating that this therapy was not effective for GBMS, and that other mechanisms likely 
contribute to chemoresistance in GBMs. 
Cancer Stem Cells 
 Research in recent years has focused on determining what cell population in GBM 
is responsible for chemoresistance.  As mentioned previously, GBMs contain a 
heterogenous mix of cells, some of which have stem cell-like properties.  These stem-like 
tumor cells are thought to be the origin of tumor formation, as well as being resistant to 
current therapies. 
 Several organs and tissues contain adult stem cells.  Adult stem cells are defined 
as cells having long-term replication potential that are capable of self-renewal and 
differentiation into the cellular components of the tissue or organ in which the adult stem 
cell resides [27, 28].  In addition to normal adult stem cells, stem cell populations have 
also been identified in many cancers, such as leukemia [29, 30], colon [31], 
retinoblastoma [32], lung [33], melanoma [34], breast [35], and brain [36, 37].  Cancer 
stem cells are defined as cancer or tumor cells that have unlimited self-renewal potential 
and are capable of forming tumors in immunodeficient mice that recapitulate the original 
tumor [38].   
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Figure 1.1:  Neurosphere cultures are capable of self-renewal, generation of many 
progeny, differentiation, and tumor formation.  A)  Neurosphere initiating cells (NICs) 
can be isolated from the subventricular zone of fetal or neonatal mice or from surgically 
resected GBM tissue.  B)  When plated into serum free media containing EGF and FGF, a 
small percent of cells, the NICs, will form neurospheres.  C)  When triturated into 
individual cells, the NICs in the culture will go on to form more neurospheres.  
Established neurosphere cultures can sometimes be maintained indefinitely.  D)  
Neurosphere cells can be induced to differentiate by removing essential growth factors.  
E)  Neurosphere cultures derived from GBMs will form tumors when transplanted into 
mice, indicating that these cultures maintain tumor-initiating cells in vitro. 
Figure modified from [39]. 
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Similar to cells isolated form the subventricular zone of fetal or neonatal mice, 
brain tumor stem cells can be isolated from primary GBMs and propagated in defined 
media as neurospheres (Figure 1.1).  When maintained properly, these neurosphere 
cultures share many properties with normal brain neurosphere stem cell cultures, 
including long-term self-renewal, multipotency, and the generation of many progeny 
[39].  Whereas non-transformed neurosphere cultures contain only 1-2% of NICs [40], 
GBM cultures have a higher percent of NICs, sometimes up to 30%, which is thought to 
correlate to the clinical aggressiveness of the tumor [38, 41, 42].  Galli et al. established 
several neurosphere cultures from primary GBMs.  When grown in media with the 
growth factors EGF and FGF, GBM-derived cell lines could be passaged over 80 times, 
indicating that cultures had maintained stem cell-like self-renewal properties.  Even after 
80 passages, the cultures were capable of undergoing terminal differentiation upon 
removal of growth factors.  Unlike normal fetal neural cells, brain tumor stem cells will 
form tumors when transplanted into immunodefient mice. Tumors that form from GBM 
neurosphere cultures are histologically similar to the original GBM [37, 42, 43].  These 
studies support the idea that cells grown in neurosphere cultures with stem-like properties 
are the source of GBM formation and sustained growth. 
 One of the most important stem cell-like characteristics of tumor-initiating 
stem/progenitor cells is increased self-renewal potential [44, 45].  Several signaling 
pathways that regulate self-renewal in normal stem cells are dysregulated in cancer stem 
cells, such as WNT, SHH, Notch, PTEN, β-catenin, TGF-β, and Bmi-1, resulting in 
enhanced self-renewal and proliferation [44, 46-49].  In addition to dsyregulated self-
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renewal, cancer stem cells can remain quiescent [49, 50].  These properties may 
contribute to the resistance of tumor stem cells to current therapies. 
 Stem cells frequently remain in a G0 quiescent state and self-renew when they 
receive appropriate signals to divide [49].  Quiescence helps preserve a stem cell‟s 
prolonged lifespan [51, 52], contributes to resistance to apoptosis [29, 53, 54], and 
prevents differentiation [55].  Transcriptional profiling of cells induced into becoming 
quiescent by mitogen withdrawal, contact inhibition, and loss of adhesion identified the 
upregulation of 116 genes and downregulation of 33 genes involved in regulating cell 
growth and division, suppression of apoptosis, and suppression of differentiation.  
Overexpression of the CDK inhibitors p21 or p27, which are involved in cell cycle arrest 
rather than G0 quiescence, blocked cell proliferation, but did not induce the same 
transcriptional pattern induced by quiescence [53].  Other reports claim that p21 [52] and 
p27 are upregulated in quiescent cells [56].   
Targeting quiescent stem cells is one approach used to treat cancer.  Stem cells 
residing in bone marrow in adult myeloid leukemia (AML) are predominantly quiescent, 
which protects them from chemotherapy-induced apoptosis [29].  Treatment with 
granulocyte colony-stimulating factor (G-CSF) induced AML stem cells to enter the cell 
cycle, which significantly enhanced the induction of apoptosis when cells were treated 
with chemotherapy [57].  Hence, cancer stem cell quiescence may be one mechanism of 
chemoresistance. 
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 Segregation of an “immortal” DNA strand during stem cell self-renewal has been 
proposed as another possible mechanism of chemoprotection in normal and cancer stem 
cells.  Stem cells are capable of undergoing DNA synthesis and division in which one 
original parental or “immortal” strand is not replicated and always segregates with the 
daughter stem cell.  This pattern of DNA synthesis and cell division ensures that the stem 
cell population does not accumulate mutations associated with replication or as a result of 
DNA damaging agents [49].  Segregation of an immortal strand of DNA within stem cell 
populations may preserve the genetic integrity of the stem cell pool by helping cells avoid 
replication and chemotherapy-induced DNA damage and hence cytotoxicity.  In addition 
to stem-cell properties that help preserve genetic integrity and hence protect against 
chemotoxicity, cancer stem cells contain a variety of mutations and mechanisms that can 
contribute to chemoresistance. 
Glioblastoma patients rarely survive more than two years after diagnosis even 
after surgery, radiotherapy, and chemotherapy.  Glioblastoma neurosphere initiating cells 
(NICs) are thought to be similar to tumor initiating cells in vivo, and will form invasive 
tumors in mice.  We were interested in determining whether glioblastoma NICs were 
resistant to chemotherapy, and if so, by what mechanism? 
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CHAPTER II: 
Chemotherapy treated glioblastoma cultures contain 
populations of chemoresistant cells and cells arrested in the cell 
cycle that may be responsible for tumor regrowth in vivo 
 
Summary 
 Glioblastoma patients rarely survive more than two years after diagnosis even 
after several rounds of surgery, radiotherapy, and chemotherapy.  Glioblastoma cells can 
be cultured in defined media as neurospheres.  Glioblastoma neurosphere-initiating cells 
(NICs) are thought to be similar to tumor-initiating cells in vivo, and will form invasive 
tumors in mice.  We used GBM neurosphere cultures to examine the effects of 
chemotherapy on these cells.  We found that neurosphere formation was inhibited at 
clinically relevant doses of chemotherapy, but that some cultures can recover after 
treatment, similar to tumor regrowth in vivo.  Hopefully this model system can help us 
better understand the effects of chemotherapy on GBM cultures so that we may improve 
future treatments.  
Introduction 
Mutations in cancer stem or progenitor cells that promote chemoresistance  
In addition to containing a population of stem-like cells that may be resistant to 
chemotherapy, GBM neurosphere cultures can also have several genetic mutations that 
can contribute to chemoresistance.  PTEN is one of the most frequently mutated genes in 
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GBMs [1, 2].  PTEN regulates the phosphoinositide-3-kinase (P13K)-Akt pathway.  Loss 
of PTEN function can result in hyperactive Akt, which can enhance cell growth, 
proliferation, and survival.  PTEN is also required for maintenance of genomic stability 
[58, 59] and p53-mediated apoptosis [58].  Disruption of PTEN therefore results in 
reduced p53-mediated apoptosis.  Hematopoietic cells in which PTEN has been deleted 
transform into transplantable leukemic cells within weeks.  PTEN deletion also promoted 
hematopoietic stem cell proliferation [60].  Brain tumor stem and progenitor cells that 
have lost PTEN function also acquire enhanced self-renewal and multipotent 
differentiation potential.  PTEN deficiency mediates enhanced self-renewal by promoting 
cells to enter the cell cycle from G0 [61], as well as accelerating the G1 to S cell cycle 
transition [62].  Mice deficient for PTEN have enlarged brains (macrocephaly) resulting 
from increased cell proliferation, decreased cell death, and enlarged cell size [63].  PTEN 
deficiency may contribute to tumor survival by enhancing self-renewal and making cells 
more resistant to apoptosis. 
The EGFR gene is amplified in many glioblastomas leading to the overexpression 
of EGFR protein [64].  Many tumors with amplified EGFR express a mutated EGFR 
[65], the most common of which is EGFRvIII.   EGFRvIII was detected in 53% of 
glioblastomas [66].  EGFRvIII has a 267-amino acid deletion in the extracellular domain 
resulting in constitutively active EGFR signaling [67].  Expression of EGFRvIII enhances 
cell proliferation, tumor growth and invasiveness [68-73].  GBM cells expressing 
EGFRvIII therefore likely contribute to increasing tumor volume. 
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 In response to DNA damage, the tumor suppressor p53 can trigger cell cycle 
arrest, apoptosis, or senescence [74].  p53 is expressed at higher levels in neural stem 
cells compared with other cells in the adult brain.  Mice lacking functional p53 have 
significantly higher numbers of proliferating cells and NICs, implicating p53 as a 
negative regulator of neural stem cell self-renewal.  p53-/- mice also had decreased levels 
of apoptotic cells when compared with p53+/+ mice [75].  Cancer development in lung 
and brain tissue is associated with inactivation of p53 and decreased apoptosis [76, 77].  
These results indicate that GBMs with mutated p53 would therefore have higher 
proliferation rates, higher numbers of proliferating NICs, and would be more resistant to 
apoptosis.   
Different methods of SC Isolation 
Stem cell marker expression is frequently used to identify and isolate normal and 
cancer stem cells [78].  Marker expression has been best characterized in hematopoietic 
tissues.  For example, both normal and adult myeloid leukemia (AML) stem cells can be 
isolated based on a CD34+/CD38- phenotype.  Only AML stem cells, but not normal 
hematopoietic CD34+/CD38- cells, show long-term engraftment and differentiation 
potential when transplanted into mice [29, 30]. 
The first stem cell marker used to successfully isolate brain tumor-initiating cells 
was CD133 [36, 79].  The enrichment of brain stem cells using CD133 expression has 
been controversial, however.  In some cases, cancer stem cells enriched by the stem cell 
marker CD133 are tumor-initiating cells. When transplanted into mice, as few as 100 
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CD133+ form a tumor, while 100,000 CD133- cells can engraft but do not form tumors 
[36].   
Several laboratories have suggested that CD133 is not an ideal cancer stem cell 
marker.  Many GBMs do not contain CD133+ cells [80].  Some high-grade CD133- 
GBMs still form tumors in immunodeficient mice [81]. In addition, CD133- cells isolated 
from CD133+ glioblastomas can form tumors in immunodeficient rats that include 
CD133+ cells [82].  For low-grade astrocytomas, the CD133+ cells that were thought to 
be cancer stem cells may be blood vessel precursor cells and hence, these tumors may 
also lack CD133+ neural/glial stem cells [83]. Although this study focuses on brain 
tumors, Shmelkov et al recently made several important observations for CD133+ cells in 
colorectal carcinomas [84]. They found that expression of CD133 in the colon is 
widespread and not restricted to stem cells, and in a serial transplantation model of 
colorectal carcinoma, CD133- tumors grow faster than CD133+ tumors. Consistent with 
this result, both the CD133+ and CD133- colorectal carcinoma cells form colonspheres. 
The cell cycle-dependence of CD133 expression may also complicate cancer stem cell 
identification [85, 86]. The neurodevelopmental markers, A2B5 and CD15, may be better 
than CD133 for the selection of glioblastoma cancer stem cells [80, 87, 88]. At this time, 
there is no consensus on the best set of markers for enrichment of cancer stem cells.   
Aside from stem cell marker expression, stem cells can also sometimes be 
isolated based on expression of the enzyme aldehyde dehydrogenase (ALDH).  
ALDEFLOUR is a fluorescent substrate of ALDH that can be used to identify, quantitate, 
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and isolate primitive cell populations in several types of tissues such as hematopoietic 
[89], mammary [90], and brain.  Freshly dissociated brain tissue contained only 0.2-0.4% 
ALDH+ cells, whereas neurosphere cultures which enrich for the growth of stem cell 
fractions contained between 3-4% ALDH+ cells.  Based on immunohistochemistry and 
RT-PCR, ALDH+ cells expressed high levels of stem cell markers when compared with 
differentiated cells.  ALDH+ cells had high engraftment and differentiation potential 
when transplanted into mice.  Neurons derived from ALDH+ cells incorporated into 
many regions of the brain [91].   
The Neurosphere Assay 
Because there is currently no fool-proof method of isolating or examining live 
brain stem cells, we decided to use a functional assay to examine stem cell proliferation 
in response to chemotherapy, assessing neurosphere formation as a measure of stem cell 
content.  Neurosphere formation is an established method used to measure neural stem 
cell content [40, 92, 93].  Neurosphere cultures are known to contain a mix of NICs and 
progenitor cells.  We refer to the entire culture as “bulk cells”.  The bulk cell population 
includes the NICs, which continuously repopulate the neurosphere culture, and the non-
NICs, which make up the majority of the neurosphere, but cannot go on to form another 
neurosphere due to reduced self-renewal capacity. 
 The GBM cells used for this assay are grown as neurospheres in defined medium 
to prevent differentiation of the cancer stem cells. Unlike serum-supplemented cultures 
derived from GBMs, GBM cells grown as neurospheres will form invasive brain tumors 
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in immunodeficient mice. In addition, based on expression profiling, neurosphere 
cultures resemble glioblastoma tumors from patients more closely than serum-
supplemented cultures [94].  However, even under these conditions, only a fraction of the 
cells are able to form new neurospheres.  This small fraction of NICs is thought to be the 
population of self-renewing stem cells maintaining the culture, which we believe 
resemble tumor initiating cells in vivo.  
To quantify the NICs, normal or transformed cells were plated at low density in 
defined medium and after 1-2 weeks depending on growth rate, the numbers of 
neurospheres that form are scored [95, 96].  For normal neural cells, this assay was 
originally thought to exclusively assess stem cell proliferation [93] but is now thought to 
also detect early progenitor cell proliferation [97-99].  It is not known whether there is a 
similar ambiguity for tumor sphere-forming cells.  Throughout this thesis, we will refer to 
the neurosphere-forming or neurosphere-initiating cells as NICs.  The goal of this study is 
to better understand the effects of chemotherapy on tumor-initiating cells, which we 
believe are represented by NICs in vitro.   
Using the neurosphere-formation assay, we find that clinically relevant doses of 
BCNU or TMZ inhibit neurosphere formation without a substantial effect on the survival 
of bulk or total cells in the culture.  This result is consistent for one normal neural 
precursor culture and six GBM cultures.  Unlike most previous studies, we examine 
neurosphere formation at several time points after chemotherapy treatment (Figure 2.1) 
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For some cultures, neurosphere formation resumes following the addition of fresh 
medium and a recovery period.  BCNU and TMZ induce S and/or G2/M cell cycle arrest 
in some of these GBM cultures, which partially reverses by seven to ten days post-
treatment.  Collectively, these results indicate that GBM NIC proliferation is selectively 
and highly sensitive to chemotherapy drugs, and in some cases, the NICs enter a 
reversible cell cycle arrest.  This reversible cell cycle arrest may protect the NICs from 
chemotoxicity [29, 54, 100, 101], allowing survival and regrowth of the culture after 
chemotherapy treatment ends.  In other cell lines, secondary sphere formation shows that 
even cultures that do not recover after a recovery period sometimes contain 
chemoresistant NICs.  Chemotherapy-treated neurosphere cells retain the ability to form 
tumors in vivo, confirming that a fraction of treated cells which we believe are the 
chemoresistant NICs survived treatment and maintained tumorgenicity.  
We quantitated neurosphere formation at several time points following 
chemotherapy treatment.  This novel approach allowed us to examine the immediate 
effects of chemotherapy on neurosphere formation, as well as the more “long-term” 
effects of chemotherapy on neurosphere cultures (Figure 2.1).  Neurosphere formation 
following chemotherapy treatment indicates that some NICs are chemoresistant and can 
proliferate in the presence of chemotherapy.  Reduced neurosphere formation following 
chemotherapy treatment indicates that a fraction of NICs were not proliferating in the  
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Figure 2.1:  Neurosphere Initiating Cell (NIC) proliferation is assessed at several 
timepoints following chemotherapy treatment in this study.   A)  Neurosphere cultures are 
triturated into single cells and treated with chemotherapy drugs.  B)  The number of 
neurospheres that originally form (7-10 days) measures NIC proliferation in the presence 
of chemotherapy.  C)  After giving NS cultures a recovery period following 
chemotherapy treatment, there is an increase in the number of neurospheres in some 
cultures.  D)  After dissociation, some 14-21day cultures form secondary spheres, 
indicating that NICs remained viable and were chemoresistant even in cell lines that did 
not show significant neurosphere recovery after a recovery period.   
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presence of chemotherapy, possibly due to quiescence or reversible cell cycle arrest 
(Figure 2.1B).  Recovery of neurosphere formation following a recovery period equal to 
the time necessary for primary neurosphere formation indicates that the NICs that did not 
proliferate in the presence of chemotherapy drugs were still viable and could resume 
neurosphere formation once chemotherapy treatment was completed (Figure 2.1C).  After 
dissociation, formation of secondary spheres from 14-20 day treated cultures indicates 
that NICs remained viable and were chemoresistant even in cell lines that did not show 
significant neurosphere recovery after a recovery period (Figure 2.1D).  Tumor formation 
from chemotherapy-treated neurosphere cultures confirms that a fraction of cells 
remained viable and tumorigenic. 
These results indicate that following chemotherapy treatment, glioblastoma 
cultures contain a heterogenous mix of chemoresistant and/or reversibly arrested or 
quiescent cells that resemble cells responsible for tumor regrowth.  This model for the 
survival and recovery of cultured GBM stem cells provides insights for tumor recurrence 
in vivo.  Hence, these in vitro assays might be a powerful tool that can be used to predict 
the effectiveness of chemotherapeutic agents in treating GBMs in vivo.   
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Materials and Methods 
Cell Culture 
 In a previous study, PTEN -/- neural precursor cells [39] were infected with a 
retrovirus bearing the human mutant receptor EGFRvIII, and we refer to these cells as 
EGFRvIII PTEN -/- cells [102]. These transformed cells formed glioblastoma-like tumors 
in immunodeficient mice, and we established the aggressive PET2 line from one of these 
tumors.  As a control, PTEN +/+ neural precursor cells were infected with an empty 
MSCV-XZ066 virus [103]. Because the retrovirus expresses GFP, we refer to these cells 
as GFP PTEN +/+ cells. Given that PET2 cells were originally derived from normal 
neurosphere cultures, using these cells allows us to compare the effects of chemotherapy 
on normal and transformed cells.   
 The rat C6 adherent glioblastoma cell line was converted to floating neurosphere 
cultures, C6NS, by replacing serum-containing media with serum-free DMEM/F12 
medium supplemented with B27 (GIBCO Carlsbad, CA), 20 ng/ml bFGF (Invitrogen 
Carlsbad, CA) and 20 ng/ml EGF.  Adherent C6 cells began forming spheres within 24 
hours of switching to serum-free media.  Kondo et al also reported the conversion of C6 
cultures to neurospheres [104].  The human glioblastoma U373MG line was placed into 
20% FBS DMEM/F12 and then into defined medium. These cells did not begin forming 
neurospheres until they had been in serum free media for approximately one month.  
Primary human glioblastoma cultures (GS7-2, GS7-25 and GS9-6) were established from 
resected tumor tissue with Institutional Review Board approval. The tumors were cut into 
small sections and disassociated with trypsin. Dissociated tumor cells were grown as 
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neurosphere cultures in DMEM/F12 medium supplemented with B27, 20 ng/ml bFGF 
and 20 ng/ml EGF. The primary glioblastoma cultures were passaged using basic solution 
to disassociate the spheres [105].  Previously established cell lines were passaged using 
trituration. 
Neurosphere Initiation Assay  
 Neurospheres were mechanically triturated into single cell suspensions or 
disassociated with basic solution [105] depending upon the cell culture and plated at 
either 1,500 cells/well in a 24-well plate or 6,000 cells/well in a 6-well plate. To measure 
the effect of chemotherapy treatment on neurosphere growth, BCNU (Sigma-Aldrich St. 
Louis, MO) or TMZ (a gift from Dr. Michael Glantz) were added to single cell 
suspensions at various concentrations. Neurospheres with at least 25 cells/sphere were 
counted after 7-10 days after addition of drug. Then, to measure recovery from drug 
treatment, cultures were supplemented with fresh media, and neurospheres were counted 
a second time, 14 to 20 days after drug treatment. The primary glioblastoma cultures 
(GS7-2, GS7-25 and GS9-6) formed spheres slightly slower than the other cultures. As a 
result, we allowed about 10 days for sphere formation by the primary cultures and 7 days 
for the other cultures.  To look at secondary sphere formation, neurospheres from the 
recovery time point were triturated into single cells and allowed form secondary spheres. 
Subcutaneous xenografts with ex vivo TMZ treatment 
U373NS neurospheres were dissociated and plated at 2.5 x 104 cells/ml in defined 
media and treated with DMSO or 200 M TMZ.  On day 7, the cells were dissociated and 
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3 x 106 live cells were re-suspended in 100 l PBS. Cells were subcutaneously injected 
into the right flank of female athymic nude mice. The mice were observed for tumor 
formation for 100 days post-injection and were sacrificed when the tumor reached a 
volume of 1.5 cm3. These procedures were approved by the University of Massachusetts 
Medical School Institute for Animal Care and Use Committee (IACUC). 
Proliferation Assay 
 Single-cell suspensions were plated at 5,000 cells/well in a 96 well plate with or 
without BCNU or TMZ. After one week, viable cells were measured using colorimetric 
assays following the manufacturer‟s instructions (Promega Corp, Madison, WI). In initial 
experiments done with GFP PTEN +/+ and PET2 cells, we used 3-[4,5-dimethylthiazole-
2-yl]-2,5-diphenyltetrazolium bromide (MTT). In later experiments with the other cell 
cultures, we used 3-[4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H- tetrazolium (MTS) because of its greater solubility. In both cases, 
mitochondria in viable cells reduce these compounds to a formazan, which is assessed by 
measuring the absorbance in a Microplate reader.  For MTT assays, absorbance is 
measured at 570nm.  For MTS assays, absorbance is measured at 490nm. 
Comet Assay 
 DNA damage was measured by a Comet Assay, using protocols and reagents 
provided by Trevigen Inc. (Gaithersburg, MD). Briefly, single cells were embedded in 
agarose, lysed and treated with an alkaline solution to unwind and denature the DNA. 
The agarose-embedded cells were then subjected to electrophoresis. Cleaved DNA 
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fragments caused by single or double stranded breaks migrate out of the nuclei and are 
detected using SYBR Green. For each experiment, at least 75 cells were examined with a 
Zeiss Axiovert S100 microscope, and DNA was quantified with OpenLab 4.0 software 
(Improvision Inc., Waltham, MA). The comet tail moment is calculated as the product of 
the tail length and the relative pixel intensity of the comet tail compared with the pixel 
intensity and the area of the nucleus.  Comet tail moments are directly proportional to the 
extent of DNA damage in the cell [4].  Comet tail moments of treated cells were 
normalized to the comet tail moments of untreated cells. 
CD133+ cell isolation using Magnetic Beads 
 CD133+ cells were isolated from GFP PTEN +/+ and PET2 cells using a Dynal 
magnet and magnetic beads. Cells were incubated with a primary rat IgG anti-mouse 
CD133 antibody (eBiosciences, San Diego, CA), followed by incubation with a 
secondary sheep anti-rat IgG antibody conjugated to Dynal magnetic beads 
(Dynal/Invitrogen, Carlsbad, CA).  Cells positive for CD133 expression were 
magnetically separated from CD133 negative cells using a Dynal magnet.  To remove 
bound beads, cells were incubated with anti-rat IgG antibody which competitively binds 
to the magnetic beads, dissociating them from the cells. 
Live cell sorting  
Live cell sorting was used to isolate live populations of cells based on marker 
expression.  GFP PTEN +/+ cells were sorted once after being labeled with a rat anti-
mouse CD133 antibody (Chemicon/Millipore, Billerica, MA) followed by an anti-rat  
26 
 
 
 
 
 
 
 
 
 
 
Table 2.1:  Summary of antibodies used to isolate CD133-expressing cells in 5 different 
cell lines.  CD133-expressing cells were isolated using either Dynal magnet-based 
isolation or live cell sorting.   
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FITC-conjugated antibody (Jackson Immunolabs, West Grove, PA).  PET2 cells were 
sorted twice using the same antibody combination used to sort GFP PTEN +/+ cells, and 
twice using a PE-conjugated anti-CD133 antibody from eBiosciences.  U373NS and 
GS9-6 cells were each sorted once after labeling with a PE-conjugated anti-human 
(epitope 2) CD133 antibody  (Miltenyi, Auburn, CA).  GS7-25 cells were sorted twice 
and U373NS cells sorted once after labeling with an APC-conjugated antibody against 
CD15 (BD Pharmingen, Franklin Lakes, NJ).  Cells were sorted on a BD FACSVantage 
DV-1 cell sorter at the UMASS Core Flow Cytometry Facility.  When enough cells were 
collected, purity checks were run on BD FACSCaliburs. 
Flow Cytometry 
 Flow cytometry was used to measure the percentage of CD133+, CD15+ and 
A2B5+ cells following treatment with chemotherapy drugs.  Cells were suspended in 
PBS containing 5% fetal calf serum, and stained with antibodies against CD133, CD15, 
and A2B5.  Mouse cells were stained with monoclonal anti-mouse CD133 antibody 
(1:100; Clone 13A4, Chemicon/Millipore Corp (Billerica, MA), followed by a secondary 
PE-conjugated antibody (1:200; Jackson ImmunoResearch, West Grove, PA).  For 
human cells, we used a PE-conjugated CD133 antibody (1:10 dilution; Clone AC141, 
Miltenyi Biotec, Auburn, CA).  CD15 and A2B5 were detected with conjugated 
antibodies: CD15-APC (1:5; Clone HI98, Pharmingen/BD Biosciences, San Diego, CA) 
and A2B5-FITC (1:450; Clone A2B5-105(7), Millipore Corp., Billerica, MA).  Marker 
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expression was measured using a Becton Dickinson FACSCalibur (BD Biosciences).  
Data was analyzed using FlowJo 7.2.2 software (Tree Star Inc., Ashland, OR). 
 To analyze cell cycle, cells were fixed with 95% ethanol for at least 24 hrs, 
washed with apoptosis buffer (PBS, 1% Triton X-100, 2 mM MgCl2) to permeabilize the 
cells, and then stained with 50 g/ml propidium iodide (Sigma-Aldrich St. Louis, MO) in 
PBS, 50 g/ml RNase, 2 mM MgCl2 for 30 min prior to analysis with the FACSCalibur. 
Data were analyzed using ModFit LT 3.0 software (Verity Software House, Topsham, 
ME). 
Identifying ALDH1-expressing cells 
ALDEFLUOR (Adagen, Durham, NC) is a compound that is metabolized by the 
enzyme Aldehyde dehydrogenase 1 (ALDH1), which is expressed in stem and progenitor 
cells in many tissues [89, 91].  Briefly, ALDEFLUOR is added to cells, freely diffuses 
into cells, and is activated by cells expressing ALDH1.  When activated, ALDH1 
activates ALDEFLOUR, which then emits a fluorescent signal which can be detected 
using the FL1 filter of a FACSCalibur.  ALDH1 activity can be quantified by analyzing 
ALDH-bright, SSC-low cells.  Diethylaminobenzaldehyde (DEAB) is an inhibitor of 
ALDEFLUOR and is used as a negative control for ALDH1 activity. 
Analysis of p53 Mutations 
 mRNA was extracted using a QuickPrep micro mRNA purification kit (GE 
Healthcare, Piscataway, NJ). One hundred ng of mRNA was incubated for 2 hrs at 37°C 
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with 1 μl of Oligo(dT)12-18 (500 μg/ml), 4 μl of 5X First strand cDNA buffer, 2 μl of 0.1 
mM DTT and 1 μl of 10 mM dNTP Mix (final volume 20 μl). Then 1 μl of SSII Reverse 
Transcriptase (200 U) was added and incubated for 50 min at 42°C, followed by heat 
inactivation for 15 min at 70°C. The p53 cDNA (2 μl) was amplified with the Platinum 
Taq DNA High Fidelity Polymerase (Invitrogen). The primers for amplification of the 
human p53 cDNA were 5‟-ATGGAGGAGCCGCAGTCAGAT-3‟ and 5‟-
TGCGCCGGTCTCTCCCAGGAC-3‟; 5‟-AAGGAAATTTGCGTGTGGAGT-3‟ and 5‟-
CAGTCGGAGTCAGGCCCTTCT-3‟. The primers for amplifying the mouse p53 cDNA 
were 5‟-TTGGGACCATCCTGGCTGTAG-3‟ and 5‟-
ATAAGGTACCACCACGCTGTG-3‟ for exon1-5, 5‟-
ATGGTGATGGCCTGGCTCCTC-3‟ and 5‟-CAGTTCAGGGCAAAGGACTTC-3‟ for 
exon 6-8, 5‟-AAGTCCTTTGCCCTGAACTGC-3‟ and 5‟-
GACCGGGAGGATTGTGTCTCA-3‟ for exon 9. The PCR products were analyzed by 
automated DNA sequencing in both directions (GENEWIZ, South Plainfield, NJ).   
 
Results 
Stem cell marker expression varied among cell lines and was not equal to the % of 
NICs 
 We analyzed several GBM cell lines for the expression of several stem cell 
markers previously used to quantify stem cell populations.  We then compared the 
percent of cells expressing stem cell markers to the percent of NICs in each culture.  
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Based on this comparison, there was no clear correlation between the percent of NICs 
detected by the neurosphere assay to the percent of cells positive for any stem cell marker 
(Table 2.2).  For example, GS9-6 cells derived from a primary GBM contained 8% NICs, 
27% CD133+ cells, 94% CD15+ cells, and 18% A2B5+ cells. 
 In addition to having no clear correlation to the percent of NICs, the percent of 
cells expressing each stem cell marker was highly variable among neurosphere cultures.  
For example, CD133 expressing cells ranged from 2-91% among the six neurosphere 
lines tested (Table 2.2, Figure 2.2).  Stem cells are thought to be only a small percent of 
any given culture or tissue [44], so it is unlikely for a culture to be composed of 91% 
stem cells. 
GBM NS cultures did not stain with ALDH1 
 Based on previous studies successfully using ALDH activity to isolate neural 
stem cells [91] and tumor cells that were resistant to alkylating agents [90], we decided to 
quantify our GBM stem cells using the reagent ALDEFLOUR.  Neither non-transformed 
GFP PTEN +/+ cells nor transformed GBM-like PET2 cells stained positive for ALDH 
(Figure 2.3). 
Sorting Based on Stem Cell Marker Expression did not Enrich for NICs 
Even though stem cell marker expression did not correlate to the percent of NICs 
in the culture, which are considered functionally to be the stem and progenitor cells 
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Table 2.2:  The percent of neurosphere-initiating cells (NICs), which are thought to be 
the stem/progenitor-like population in these cultures, does not correlate with the percent 
of cells staining for any of the stem-cell markers used in this study.   
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Figure 2.2:  The percent of cells expressing CD133 was highly variable among the six 
neurosphere cultures tested. The % of NICs is listed for comparison. CD133 expression 
levels were assayed using flow cytometry in (a) GFP PTEN +/+, a non-transformed cell 
line, (b) PET2, a GBM-like line generated in our lab, (c) U373NS, a previously 
established GBM cell line, and (d-f) GS7-2, GS7-25, and GS9-6, three primary GBM cell 
lines.  The x-axis if FL1 (FITC+) and the y-axis if FL2 (PE+). 
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Figure 2.3:  ALDH expressing stem and progenitor cells can be quantitated using a 
fluorescent substrate of ALDH called Aldefluor which fluoresces following exposure to 
ALDH.  DEAB is an inhibitor of Aldefluor used as a negative control.  When Aldeflour 
was added to cells, neither (A) non-transformed GFP PTEN +/+ cells nor (B) transformed 
GBM-like PET2 cells stained positive for ALDH activity.  (C) ALDH+ staining in neural 
stem cells.  The x-axis is FL1, and the y-axis is SSC. 
Figure modified from [91]. 
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maintaining the culture, we decided to sort cells to see if markers could be used to isolate 
proliferating neurosphere-initiating populations.   
CD133 
 CD133 expression has been used to isolate neurosphere-initiating and tumorigenic 
brain stem and progenitor cells in many studies [36, 37, 106].  Based on these studies, we 
isolated or sorted GFP PTEN +/+, PET2, U373NS, and GS9-6 cells to see if we could 
also enrich for NICs based on CD133 expression.  
  CD133-positive and negative cells from non-transformed GFP PTEN +/+ and 
transformed PET2 cells were first isolated using magnetic beads and a Dynal magnet 
(Figure 2.4).  When plated out for a neurosphere assay, CD133+ cells formed only 
minimal numbers of neurospheres, indicating that magnetic sorting of CD133+ cells did 
not enrich for neurosphere initiating fractions in GFP PTEN +/+ (not shown) or PET2 
cells (Figure 2.5). 
CD133-positive and negative cells from non-transformed GFP PTEN +/+, 
transformed PET2, U373NS, and GS9-6 cells were then isolated using live cell sorting, 
which was frequently cited in literature as a method of stem cell isolation (Figure 2.6).  
As mentioned previously, CD133 expression levels varied among cell lines (Fig 2.2).  
GFP PTEN +/+ cells were sorted once and PET2 cells sorted four times using FITC-
labeled anti-mouse CD133 antibodies.  Sorted cells were then plated out so that we could  
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Figure 2.4:  Magnetic beads conjugated to an antibody against a primary anti-CD133 
antibody were used to separate CD133+ and CD133- cells using a Dynal magnet. A) 
Cells are labeled with an IgG antibody against CD133, followed by incubation with 
magnetic beads bound to an anti-IgG antibody. B) Magnetically labeled CD133+ cells 
can be isolated by pulling the labeled cells out of the total population using a Dynal 
magnet.  C) Unlabeled cells are harvested from the supernatant, and labeled cells are held 
against the magnet until ready for harvest.  D) Once CD133+ cells are harvested, they can 
be incubated with antibody to dissociate bound beads.   
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Figure 2.5:  CD133+ and CD133- cells were isolated using Dynal magnetic beads, and 
were then plated out for neurosphere assays.  After being plated, only CD133- cells but 
not CD133+ cells isolated from PET2 cells formed neurospheres.  Similar results were 
seen for GFP PTEN +/+ cells. 
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Figure 2.6:  Live cell sorting was used to isolate cells based on stem cell marker 
expression.  A) Cells are fluorescently labeled with antibodies against specific markers, 
in this figure CD133 is used as an example. B)  Live cell sorters are used to separate C) 
fluorescently labeled marker+ and marker- cells, which can then be used for further 
analysis.   
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observe cell proliferation and sphere formation.  Similar to results obtained with 
magnetic bead isolation, following all five sorts, only CD133 negative fractions of cells 
proliferated or formed neurospheres.  Whereas CD133+ cells did not proliferate even 
after a month‟s time in growth factor enriched media, CD133- cells began proliferating 
within 2 days of sorting.  We observed the same results for the established human cell 
line U373NS and the primary human GBM cell line GS9-6.   Three weeks after plating, 
primary GS9-6 CD133+ cells had formed an average of 6 (±7) spheres per well, whereas 
CD133- cells had formed 163 (±25) spheres (Figure 2.7).  These results are similar to and 
representative of the results seen with the other cell lines tested. 
CD15 
CD15 expression has also been used to isolate highly tumorigenic self-renewing 
GBM cells [80].  To see if we could enrich for self-renewing and proliferating 
neurosphere cells, we sorted U373NS and GS7-25 cells based on CD15 expression.  
CD15-positive and negative cells isolated by live cell sorting from U373NS (Figure 
2.8A) and GS7-25 (Figure 2.8 B) formed similar numbers of neurospheres.  For example, 
U373NS CD15+ and CD15- cells formed 33 (± 20) and 50 (± 17) neurospheres 
respectively, and GS7-25 CD15+ and CD15- cells formed 77 (± 12) and 81 (± 27) 
neurospheres respectively. 
Neurosphere formation is inhibited at lower concentrations of chemotherapy drugs 
than those required to inhibit bulk cell proliferation 
The goal of this study is to better understand the effects of chemotherapy on  
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Figure 2.7:  CD133+ and CD133- cells were isolated using live cell sorting, and were 
then plated out for neurosphere assays.  Shown here is the result of a neurosphere assay 
of sorted primary GS9-6 cells.  After being plated, only CD133- cells but not CD133+ 
cells proliferated or formed neurospheres.  This pattern of exclusive proliferation of the 
CD133-cell fraction is consistent for all of the cell lines sorted for CD133 expression. 
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Figure 2.8:  CD15+ and CD15- cells were isolated using live cell sorting, and were then 
plated out for neurosphere assays.  CD15-positive and negative cells isolated by live cell 
sorting from (A) U373NS and (B) GS7-25 formed similar numbers of neurospheres, 
indicating that CD15 expression did not enrich for NICs. 
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tumor-initiating cells, which we believe are represented by NICs in vitro.  To determine 
how chemotherapy drugs affect neurosphere formation, which is a measure of NIC 
proliferation, we measured neurosphere formation in non-transformed and GBM 
neurosphere cultures without or with treatment with BCNU or TMZ.  Because of their 
rapid decay in aqueous solution [107, 108], these drugs likely persist only a few hours, 
but their effects on tumor cells last longer [109]. After 7 or 10 days, we counted the 
number of neurospheres that formed without or with drug treatment.   For these 
experiments, we quantified neurosphere formation after drug treatment for the non-
transformed GFP PTEN +/+ and transformed GBM-like PET2 cells derived from non-
transformed (Figure 2.9 A,B), the established rat cell line C6NS, the established human 
cell line U373NS (Figure 2.9 C,D), and three primary GBM cell lines GS7-2, GS7-25, 
and GS9-6 (Figure 2.9 E,F).  When starting these experiments, we had expected that 
NICs would be resistant to chemotherapy, and would continue proliferating even when 
treated with chemotherapeutic agents.  Following treatment with BCNU or TMZ, 
however, neurosphere formation was inhibited at fairly low concentrations of drugs in a 
dose-dependent manner (Figure 2.9).   
To determine the sensitivity of bulk or total cells to chemotherapy, we 
performed MTT or MTS assays to measure the total number of viable cells in cultures at 
the time that the neurospheres were counted after treatment with either BCNU or TMZ.  
Data from MTT assays done with non-transformed GFP PTEN +/+ and PET2 total cells 
indicates that TMZ may be less toxic to non-transformed cells compared with BCNU 
(Figure 2.10).  MTS assays done with GBM cultures indicate that the total cells in some  
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Figure 2.9:  We determined how chemotherapy drugs affect neurosphere formation and 
proliferation by quantifying neurospheres 7-10 days after BCNU or TMZ treatment of 
single cell suspensions for A,B) the non-transformed GFP PTEN +/+ cells, transformed 
PET2 cells derived from non-transformed GFP PTEN +/+ cells, C,D) the established rat 
cell line C6NS, the established human cell line U373NS, and D,E) three GBM primary 
human cell lines: GS7-2, GS7-25, and GS9-6.  Following treatment with BCNU or TMZ, 
neurosphere formation was inhibited at fairly low concentrations of drugs in a dose-
dependent manner for all cell lines tested. 
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cultures, such as GS9-6, are more sensitive to the chemotherapy drugs compared with 
other lines (Figure 2.11).  Overall, inhibition of bulk cell proliferation compared with 
neurosphere formation showed that bulk cell growth inhibition required higher doses of 
chemotherapy drugs for all cultures tested (Figure 2.10 and Figure 2.11).   
To clearly show the difference in drug concentration required to inhibit 
neurosphere formation compared with inhibiting bulk or total cell proliferation, we 
calculated the drug concentrations at which neurosphere formation was inhibited by 50% 
(IC50), the drug concentrations at which bulk cell numbers were decreased by 50% 
(MTS/MTT IC50) and the concentration at which bulk cells numbers were decreased by 
90% (MTS/MTT IC90) (Figure 2.12 and 2.13). GFP PTEN +/+ and PET2 cells had 
similar sphere IC50 values for treatment with BCNU or TMZ.  The MTT IC50 and MTT 
IC90 values were both 5-fold (BCNU) and 1.4-2.0-fold (TMZ) higher for PET2 than for 
GFP PTEN +/+, indicating that normal GFP PTEN +/+ bulk cells are more sensitive to 
BCNU and TMZ than the transformed PET2 cells (Figure 2.12 A-B). 
The sensitivities of the GBM cultures to BCNU and TMZ varied, but there was 
one consistent finding. The concentration of chemotherapy drug required to inhibit  
neurosphere formation is much less than that required to inhibit bulk cell proliferation. 
The MTS IC50‟s for the inhibition of bulk cell proliferation following BCNU treatment 
were 2.5 to 40 fold higher than those for sphere formation. For TMZ, the MTS IC50‟s 
were 5 to 240 fold higher than sphere IC50‟s. Finally, the IC90 values were substantially 
higher than the sphere IC50‟s for both BCNU and TMZ (Figure 2.13 A-B), indicating that  
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Figure 2.10:  We determined the sensitivity of bulk or total cells in non-transformed GFP 
PTEN +/+ and transformed PET2 cultures to BCNU or TMZ by doing MTT assays to 
measure the total number of viable cells in the culture with or without treatment.  GFP 
PTEN +/+ and PET2 bulk cell proliferation was inhibited at much higher doses of drug 
when compared with neurosphere inhibition following treatment with A) BCNU or B) 
TMZ.  Also, non-transformed bulk cells seem less sensitive to TMZ compared with 
BCNU. 
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Figure 2.11:  We determined the sensitivity of bulk or total cells in GBM lines C6NS, 
GS7-2, GS7-25, and GS9-6 cultures to A) BCNU or B) TMZ using MTS assays to 
measure the total number of viable cells in the culture with or without treatment.  In most 
cell lines, inhibition of GBM bulk cell proliferation required much higher doses of BCNU 
or TMZ compared to doses used to efficiently inhibit neurosphere formation. 
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Figure 2.12:  We calculated the drug concentrations at which neurosphere formation was 
inhibited by 50% (IC50), the drug concentrations at which total cell numbers were 
decreased by 50% (MTS/MTT IC50) and the concentration at which total cells numbers 
were decreased by 90% (MTS/MTT IC90).  Shown here are values for A) BCNU treated 
and B) TMZ treated non-transformed GFP PTEN +/+ and transformed PET2 cells. 
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Figure 2.13:  We calculated the drug concentrations at which neurosphere formation was 
inhibited by 50% (IC50), the drug concentrations at which total cell numbers were 
decreased by 50% (MTS/MTT IC50) and the concentration at which total cells numbers 
were decreased by 90% (MTS/MTT IC90).  Shown here are values for five GBM NS 
cultures that were A) treated with BCNU or B) TMZ. 
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sphere formation which measures NIC proliferation is inhibited at much lower doses of 
drug than that required to induce substantial toxicity. 
 
Chemotherapy Treatment Does Not Have a Consistent Effect on Stem Cell Marker 
Expression 
To further study the effects of chemotherapy drugs on glioblastoma cells, we 
quantified the percentages of cells expressing the stem cell markers CD133, CD15, and 
A2B5 by flow cytometry before and after chemotherapy treatment.  We analyzed cells 
treated with 50 µM BCNU and 200 µM TMZ for these studies because these 
concentrations block neurosphere formation by at least 80% but have only a modest 
effect on the number of total cells. Flow cytometry analysis shows that the percent of 
CD133+ cells decreased from 4.7 ± 0.9 in untreated PET2 cultures to 1.9 ± 0.7 (p=0.04) 
in cultures treated with 50 µM BCNU.  The percentages of CD133+ cells did not 
significantly decrease for the other cell lines tested.  Changes in the percentages of 
CD15+ cells following chemotherapy treatment are inconsistent between cell lines.  For 
GS7-2, the percentage of CD15+ cells decreased from 86 ± 1% to 61 ± 5% (p<0.02), but 
the other cell lines did not show significant change.  The percentages of A2B5+ cells 
significantly increased following chemotherapy treatment for PET2, U373NS and GS7-2 
but not for GS7-25 and GS9-6 (Table 2).  In summary, the baselines and changes in 
expression levels of the stem cell markers CD133, A2B5 and CD15 following 
chemotherapy treatment varied between cell lines. The neurosphere assay, on the other 
hand, provided a much more consistent result. Based on decreased neurosphere  
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Table 2.3:  PET2, U373NS, GS7-2, GS7-25, and GS9-6 cells were analyzed for the 
expression of stem cell markers before and after chemotherapy treatment using flow 
cytometry.  The baselines and changes in expression levels of the stem cells markers 
CD133, CD15, and A2B5 following chemotherapy treatment were inconsistent among 
neurosphere cultures. 
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formation, we conclude that stem cell proliferation is more sensitive to chemotherapy 
drugs than bulk cell proliferation. 
For some cell lines, NS formation resumes following a recovery period after 
chemotherapy treatment 
 Chemotherapy treatment resulted in a drastic reduction in neurosphere formation.  
Although neurosphere formation was inhibited, cells remaining after treatment appeared 
viable, with some cells looking very enlarged.  To see if neurosphere formation would 
resume following chemotherapy treatment, we observed treated cultures after giving 
them time to recover.  Essentially, chemotherapy treated cultures were given fresh media, 
re-incubated, and examined for resumed growth.  The treated cells had several possible 
fates (Figure 2.14).  Of the cells that did not proliferate, some may have died, some may 
have differentiated, and some may have entered a senescent state.  Dead, differentiated, 
and senescent cells would not be capable of forming neurospheres, and would not be able 
to restore a culture.  If NIC proliferation is inhibited in the presence of drug, but can be 
restored after a recovery period, NICs are most likely in a quiescent or reversibly arrested 
state. 
To determine if neurosphere formation resumes after chemotherapy treatment, 
neurospheres were counted after a recovery period. Experiments were done with cultures 
treated with 50 µM BCNU or 200 µM TMZ, which greatly decreased initial neurosphere 
formation (Figure 2.9). Specifically, initial neurospheres were counted 7 or 10 days 
(based on culture growth rate) after the addition of chemotherapy drugs. Then, fresh  
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Figure 2.14:  Following chemotherapy treatment, GBM cultures contain a heterogeneous 
mix of cells: cells that have died, differentiated, or become senescent.  There may also be 
populations of chemoresistant cells, and/or cells that have become quiescent or have 
arrested in the cell cycle that may be representative of cells contributing to tumor 
regrowth in vivo.   
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medium was added, and the culture was allowed to recover for an additional 7-10 days of 
in the absence of drugs.  Neurospheres counted after the recovery period include both the 
initial spheres formed by day 7 or 10 and new spheres that formed during the recovery 
period (Figure 2.15). 
The cultures varied greatly in their recovery from the two chemotherapy 
drugs.  Normal GFP PTEN +/+ cells did not recover from 50 µM  BCNU treatment, but 
did recover from 200 µM TMZ treatment (5-fold increase in sphere formation 
approaching statistical significance, p<0.13), indicating that 200 µM TMZ is less toxic to 
normal neural precursor cells compared with 50 µM BCNU.  The transformed PET2 cells 
showed dramatic 13- and 17-fold increases in the number of spheres following BCNU 
and TMZ treatments, respectively (Figure 2.15 A).  For U373NS, the number of 
neurospheres increased nearly 2-fold during the recovery period for both BCNU and 
TMZ (Figure 2.15 B).  For GS7-2, there was a dramatic 5-fold increase in neurospheres  
during the recovery period after 50 µM BCNU treatment. In contrast, the GS7-2 
neurospheres did not increase significantly after treatment with 200 µM TMZ (Figure 
2.15 C).  For both chemotherapy drugs, the number of neurospheres for C6NS, GS7-25, 
and GS9-6 cultures did not significantly increase in the recovery period (Figure 2.15 
B,C).  These results indicate that some treated cultures contain NICs that may have 
entered a quiescent or reversibly arrested state following chemotherapy treatment. 
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Figure 2.15:  Neurospheres were counted after a recovery period (“R”).  Some cultures 
such as PET2, U373NS, and GS7-2 showed significantly increased neurosphere 
formation after a recovery period.  These results indicate that some treated cultures 
contain NICs that may have entered a quiescent or reversibly arrested state following 
chemotherapy treatment. 
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MTS recovery 
To determine the effects of chemotherapy on the total or bulk cells in neurosphere 
cultures after a recovery period, we performed MTT or MTS assays following the 
recovery period (Figure 2.16).  MTT data indicates that non-transformed GFP PTEN +/+  
cultures were no longer viable two weeks after BCNU treatment, whereas a fraction of 
PET2 positive cells had remained viable.  Both GFP PTEN +/+ and PET2 cultures 
contained viable fractions of total cells two weeks after TMZ treatment (Figure 2.16 A).  
MTS data collected from the other GBM neurosphere cultures indicated that all cultures 
contain a fraction of viable cells following chemotherapy and a recovery period (Figure 
2.16 B,C). 
 
Secondary Sphere formation shows that NICs are restoring GBM cultures 
To measure maintained NIC viability and self-renewal after chemotherapy 
treatment, we also measured secondary sphere formation.  In these experiments, 14 or 20 
day cultures were titrated into single cells, and sphere formation was measured to see if 
NICs were still capable of repopulating the culture (Figure 2.17).  The lack of recovery 
from 50 µM BCNU for GFP PTEN +/+ cells was confirmed by the lack of secondary 
sphere formation.  GFP PTEN +/+ cells formed secondary spheres following 200 µM 
TMZ treatment, confirming that 200 µM TMZ was less toxic to these normal 
neurosphere cells compared with 50 µM BCNU.  PET2 and U373NS cells formed 
secondary spheres following treatment with both drugs.  GS7-2 formed secondary sphere  
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Figure 2.16:  We repeated MTT or MTS assays after a recovery period (“R).  MTS 
recovery data indicates that ~two weeks after treatment, all of the GBM lines contain a 
population of viable cells.     
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Figure 2.17:  We quantitated secondary sphere formation after chemotherapy treatment.  
After a recovery period, cultures were resuspended into single cells, and the number of 
secondary spheres that formed was quantitated.  PET2, GS7-2, and U373NS cultures 
maintained viable NICs that were capable of forming secondary spheres after BCNU 
treatment.  GFP PTEN +/+, PET2, and U373NS cultures contained viable NICs that were 
capable of neurosphere formation following TMZ treatment. 
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formation following treatment with 50 µM BCNU but not 200 µM TMZ. GS9-6 did not 
form secondary neurospheres after treatment with 50 µM BCNU or 200 µM TMZ. 
In summary, for some cell cultures, inhibition of neurosphere formation by the 
chemotherapy drugs TMZ and BCNU is reversible. Following a recovery period, some  
cultures show a robust increase in neurosphere formation, indicating that NICs were 
viable but did not proliferate during chemotherapy treatment. Even for lines that did not  
show 14 day recovery, secondary sphere formation confirmed that some NICs avoided 
chemotoxicity and restored the neurosphere cultures. 
 
TMZ-treated cultures maintained their tumorgenicity  
 After demonstrating that some NICs treated with clinically relevant TMZ 
concentrations are capable of recovery and/or secondary sphere formation indicating that 
they are repopulating the culture, we wanted to determine whether the cells that survive 
and recover are still tumorigenic. To test this, U373NS cultures were treated with DMSO 
control or 200 M TMZ and injected subcutaneously into the right flank of nude mice.  
The control DMSO treated cells formed palpable tumors in an average of 15 days for 7/7 
xenografts.  TMZ treatment increased the latency of tumor formation, however, the tumor 
incidence was similar to the DMSO control xenografts. Palpable tumors formed for 6/7 
TMZ-treated U373NS xenografts in an average of 43 days, indicating that TMZ treated 
NICs maintained tumorgenicity (Figure 2.18).  
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Figure 2.18:  To determine if GBM neurosphere cultures remained tumorigenic after 
chemotherapy treatment, treated cells were subcutaneously injected into the right flank of 
nude mice.  U373NS cells were treated with DMSO as a control or TMZ.  Although the 
latency of tumor formation was increased following TMZ treatment, chemotherapy 
treated neurosphere cells were still capable of forming tumors.  20 days after injection, 
DMSO treated U373NS cells had formed tumors in 7/7 mice.  70 days after injection, 
TMZ treated U373NS cells had formed tumors in 6/7 mice. 
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The tumor suppressor p53 is mutated in some GBM cell cultures 
 The tumor suppressor p53 plays a role in many cellular functions, including DNA 
damage signaling, proliferation, and resistance to apoptosis.  p53 cDNA was sequenced 
to determine if our cell lines contained any p53 mutations (Table 3).  Non-transformed 
GFP PTEN +/+ and primary human GBM GS7-2 and GS9-6 cultures had the wild type 
p53 sequence.  PET2 cultures had a C132W mutation, which was transcriptionally 
inactivated as judged by a WAF1 reporter construct [102].  GS7-2 cultures had a mutated 
F113V sequence. Amino acid 113 mutation has been documented thus far in four tumors 
(Sanger Cosmic Database), including one F113V mutation in a glioblastoma.  The 
parental line of U373NS, U373MG, is already known to lack functional p53 [18]. 
Normal and Transformed Neurosphere Cultures Accumulate DNA Damage, 
Indicating that Survival and Recovery are not Solely DNA Damage Dependent 
 We found that the transformed PET2 neurosphere cultures were more resistant to 
treatment with chemotherapy drugs, in particular to TMZ, than the normal GFP PTEN  
+/+ neurosphere cells (Figure 2.15).  To determine if this resistance was due to a lack of 
DNA damage, we used the comet assay to measure accumulated DNA damage in 
untreated GFP PTEN +/+ and PET2 neurosphere cells and cells treated with 50 M 
BCNU or 200 M TMZ.  Following treatment with 50 M BCNU, GFP PTEN +/+ and 
PET2 cells had 6.1 ± 0.4 and 4.7 ± 1.6 fold increases in comet tail moments, respectively, 
demonstrating a similar degree of DNA damage (Figure 2.19 A). Treatment with 200 M 
BCNU resulted in even greater increases (34 ± 12 fold) in comet tail moment for PET2  
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Table 2.4:  Non-transformed and GBM cell lines were tested to determine whether they 
expressed wild-type or mutant forms of p53.  Non-transformed GFP PTEN +/+, GS7-25, 
and GS9-6 expressed wild-type p53.  Transformed PET2 and GBM cell lines U373NS 
and GS7-2 expressed mutant forms of p53. 
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Figure 2.19: We used the comet assay to assess DNA breaks in GFP PTEN +/+ and 
PET2 cells. Data are presented as the ratio of the comet tail moments of treated to 
untreated cells. (A) Following treatment with 50 M BCNU, GFP PTEN +/+ and PET2 
cells accumulated a similar number of DNA breaks.  PET2 cells showed more DNA 
breaks after treatment with 200 M BCNU. (B) PET2 cells accumulated more DNA 
breaks compared with GFP PTEN +/+ following treatment with 200 or 800 M TMZ. 
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cells. Following treatment with 200 M TMZ, GFP PTEN +/+ and PET2 cells comet tail 
moments increased 2.0 ± 0.2 and 10 ± 4 fold, respectively. Thus, contrary to the similar 
extent of DNA damage observed following 50 M BCNU treatment, PET2 cells 
accumulated more DNA damage than GFP PTEN +/+ cells following treatment with 200 
M TMZ (Figure 2.19 B). PET2 cells treated with 800 M TMZ also sustained more 
damage (29 ± 10 fold) than GFP PTEN +/+ cells (4 ± 2 fold).  Therefore, we concluded 
that PET2 cells are not resistant to accumulating DNA damage, and the relative resistance 
of the PET2 cells compared with GFP PTEN +/+ cells is not due to a lack of DNA 
damage. 
Some neurosphere cultures undergo reversible cell cycle arrest 
Based on the observation that some chemotherapy treated cells looked very 
enlarged, resembling cells arrested in the cell cycle, we decided to analyze the cell cycle 
profiles of our cultures.  To determine whether cells undergo cell cycle arrest in response 
to treatment with 50 M BCNU or 200 M TMZ, we carried out propidium iodide flow 
cytometry on treated and untreated cultures.  Propidium idodide flow cytometry has been  
extensively used to analyze cell cycle stage and apoptosis [110].  Originally, we analyzed 
cells 10 days after the addition of chemotherapy drugs for the primary lines and 7 days 
after addition of drugs for the other lines. At 7-10 days, the most heavily damaged cells 
were dead, allowing us to analyze the cell cycle profiles of the surviving cells. The results 
varied depending upon the cell line and the drug treatment.  GFP PTEN +/+ cells treated 
with 50 M BCNU were not viable, resulting in mostly cell debris (Figure 2.20).  The  
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Figure 2.20:  We analyzed the cell cycle status of neurosphere cultures before and after 
chemotherapy treatment using propidium iodide FLOW cytometry. These data 
demonstrate cell death, an increased fraction of cells in G2/M or S phase, or both 
following drug treatment of the non-transformed GFP PTEN +/+ neurospheres and three 
primary glioblastoma neurosphere cultures. 
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profile of GFP PTEN +/+ cells following treatment with 200 M TMZ was 
indistinguishable from untreated cells.  GS9-6 cells treated with either 50 M BCNU or 
200 M TMZ also were mostly cell debris.  The other glioblastoma cell lines tested were 
viable.  A fraction of GS7-2 cells were in G2/M phase for BCNU and S phase for TMZ.  
There was an increase of GS7-25 cells in G2/M phase following treatment with BCNU.  
These data demonstrate cell death, an increased fraction of cells in G2/M or S phase, or 
both following drug treatment of the non-transformed GFP PTEN +/+ neurospheres and 
three primary glioblastoma neurosphere cultures.  
To more closely monitor the cell cycle stages of PET2 and U373NS cells, cultures 
that underwent significant recovery of NIC proliferation after  treatment with both BCNU 
and TMZ, we did cell cycle analysis of these cultures three and seven days after 
treatment.  In response to 50 M BCNU or 200 M TMZ, PET2 and U373NS cells 
showed accumulation of cells in S and/or G2/M when analyzed three days post-treatment 
(Figure 2.21).  We next tested whether cells resumed a normal cell cycle profile.  At 7 
days post- treatment, the profiles for PET2 cells resembled those for untreated cells 
except for increased debris. The profile for BCNU-treated U373NS cells 7 days post-
treatment showed a smaller fraction of cells accumulated in G2/M as well as increased 
debris.  For TMZ-treated U373NS cells, the G2/M accumulation had dissipated, but there 
were cells still accumulated in S phase. Overall, we see a smaller fraction of cells arrested 
in G2/M at seven days compared with three days for PET2 and U373NS (Figure 2.21).  
These results indicate that these cultures have undergone reversible cell cycle arrest in  
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Figure 2.21:  To more closely monitor the cell cycle stages of PET2 and U373NS cells, 
cultures that underwent significant recovery of NIC proliferation after  treatment with 
both BCNU and TMZ, we did propidium iodide flow cytometry of these cells three and 
seven days after treatment.  These results indicate that these cultures have undergone 
reversible cell cycle arrest in response to BCNU and TMZ.   
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response to BCNU and TMZ.  The recovery of neurosphere formation in the recovery 
week (Figure 2.15), suggests that NICs are included in the reversibly arrested fractions. 
 
Chk1/2 inhibitors in combination with chemotherapy did not prevent NIC recovery 
Previous studies have shown that combining chemotherapy treatment with Chk1 
inhibitors enhances the cytotoxic effects of chemotherapy [79, 111].  Based on these 
studies, we decided to treat GBM neurosphere cultures that underwent reversible cell 
cycle arrest with a combination of chemotherapy and Chk1 or Chk1/2 inhibitor to see if 
we could inhibit NIC recovery and enhance cyotoxicity.  Combined treatment of 
PET2NS and U373NS cultures with chemotherapy drug and the Chk1 inhibitor 
isogranulatamide (ISO) did not significantly inhibit neurosphere formation.  Recovery of 
neurosphere formation was decreased in U373NS with combined treatment, but this 
inhibition of recovery was not significant (Figure 2.22).  Combined treatment of PET2 
and U373NS cultures with chemotherapy drug and the Chk1/Chk2 inhibitor 
debromohymenialdisine (DBH) seemed to decrease recovery of neurosphere formation 
compared to chemotherapy treatment alone, but this reduced NIC recovery was also not 
significant (Figure 2.23). 
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Figure 2.22:  Chemotherapy drug and the Chk1 inhibitor Isogranulotamide (ISO) were 
added to cultures concomitantly to see if combined treatment could prevent neurosphere 
recovery and enhance chemotoxicity.  Combined treatment of PET2NS and U373NS 
cultures with chemotherapy drug and the Chk1 inhibitor ISO did not significantly inhibit 
neurosphere formation.  Recovery of neurosphere formation was decreased in U373NS 
with combined treatment, but this inhibition of recovery was not significant. 
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Figure 2.23:  Chemotherapy and the Chk1/2 inhibitor DBH were added to cultures 
concomitantly to see if combined treatment could enhance chemotoxicity.  Combined 
treatment of PET2 and U373NS cultures with chemotherapy drug and the Chk1/Chk2 
inhibitor DBH seemed to decrease recovery of neurosphere formation compared to 
chemotherapy treatment alone, but this reduced NIC recovery was not significant. 
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Discussion 
Using the neurosphere assay as an in vitro assay to predict the efficacy 
of chemotherapy treatment in vivo 
 We were interested in determining the effects of chemotherapy in GBM-initiating 
progenitor cells, which we believe are represented by NICs in vitro.  Sorting for 
previously established stem cell markers did not enrich for proliferating cells, nor did the 
expression of stem cell markers correlate to the percent of NICs in our neurosphere 
cultures.  Counting the number of neurospheres that form after plating single cells is a 
method of quantitating proliferating NICs in a culture.  The neurosphere assay is a classic 
procedure used to measure neural stem or progenitor cell content which we have used 
throughout our studies.   
 There are several possible reasons explaining why previously established stem 
cell markers, such as CD133, did not enrich for proliferating or neurosphere-initiating 
cells in our culture system.  For example, some reports claim that CD133 expression is 
cell cycle dependent [85, 86].  CD133-expressing neural stem cells are found to be 
predominantly in the S, G2, or M phase of the cell cycle, whereas CD133 negative cells 
primarily reside in G1/G0 [86].  The same accumulation of CD133 negative cells in 
G1/G0 was also observed in embryonic stem, colon cancer, and melanoma cells.  When 
CD133-negative cells are cultured after sorting, a fraction of cells resume expressing 
CD133 [85], similar to results we observed after sorting (data not shown).  These results 
indicate that CD133 expression may correlate more with cell-cycle status than stem cell-
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like properties such as self-renewal. Worth mentioning perhaps is that prolonged G0 
arrest or quiescence is characteristic of stem-cells.  A lack of CD133 expression therefore 
may be more effective if used in combination with another stem cell marker to isolate 
quiescent stem cells. 
 Although CD133 expression has been used to isolate tumor-initiating stem cells 
[36], not all tumors express CD133 [80-82].  Reports show that 27% of cell lines derived 
from primary GBMs [81] and 40% of freshly isolated GBM specimens do not contain 
CD133-expressing cells [80].  CD133-negative cells isolated from primary GBMs were 
still capable of forming tumors in nude mice [81] and rats [82].  Fifty percent of tumors 
formed from CD133-negative primary GBM cells contained a population of cells that 
expressed CD133 [82].  Overall, these results show that CD133 expression varies among 
primary GBMs, CD133-negative cells are tumorigenic, and that CD133 expression can 
be restored in tumors derived from CD133-negative cells. 
  Because of controversies surrounding stem cell isolation using stem cell markers, 
we used the neurosphere assay to measure stem/progenitor cell content.  To determine the 
“long-term” effects of chemotherapy treatment on NICs, we devised an assay to measure 
the recovery of neurosphere formation after treatment.  We treated neurosphere cultures 
with clinically relevant doses of chemotherapy drugs that drastically inhibited 
neurosphere formation, counted the neurospheres that formed after 7-10 days, and again 
counted neurospheres after an additional 7-10 days.  Surprisingly, although chemotherapy 
treatment initially drastically inhibited sphere formation, some neurosphere cultures 
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resumed neurosphere formation after a recovery period.  Thus, for some cultures, the 
inhibition of neurosphere formation in response to chemotherapy treatment was not due 
to exclusively to chemotoxicity or senescence, but perhaps due to the inhibited 
proliferation of NICs.   
MTS recovery data indicates that two weeks after treatment, all of the GBM lines 
contain a population of viable cells.  Although a fraction of total cells remains viable after 
chemotherapy treatment, NICs do not recover for all cultures.  In cultures in which NIC 
proliferation is not restored, it is likely that the total cells eventually undergo mitotic 
catastrophe, or perhaps differentiate and lose the capability to restore the culture.  In 
cultures in which NIC proliferation is restored, the total cells may be undergoing mitotic 
catastrophe or naturally dying off, but populations of total cells will likely be restored by 
the viable NICs.   
We also performed secondary sphere assays in which treated NICs were allowed 
to form neurospheres that were dissociated and replated to allow for “secondary sphere 
formation”.  Secondary sphere formation confirmed that some NICs treated with 
clinically relevant doses of chemotherapy had avoided chemotoxicity and were capable of 
restoring the culture.  In addition, TMZ-treated neurosphere cultures were capable of 
forming tumors, once again confirming that a fraction of GBM initiating cells had 
remained viable and tumorigenic.   
Although the neurosphere assay is a classic assay used to measure neural 
stem/progenitor cell content, there are some limitations to this culture system.  First of 
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all, in vitro and in vivo environments are very different.  In vitro, neurospheres are 
cultured on plastic in growth-factor enriched media.  Whereas this culture system 
enriches for neural stem/progenitor cell growth, it is very different from the in vivo 
environment in which GBM stem/progenitor cells are maintained.  Whereas growth 
factors are added to neurosphere culture media to promote stem/progenitor proliferation, 
a larger fraction of stem/progenitor cells likely remains quiescent in vivo [112].  
Alternatively, some researchers believe that stem/progenitor cells require a specific in 
vivo environment or “Niche” to be maintained properly [113-115].  Nestin+/CD133+ 
brain cancer stem/progenitor cells localize to capillaries in brain tumors.  Brain 
endothelial cells secrete factors that help maintain brain cancer stem/progenitor cells in a 
self-renewing, undifferentiated state [113].  In order to grow cells more closely 
resembling patient tumors, some researchers believe that surgically removed tumor tissue 
should be injected into anatomically equivalent locations in immune-deficient mouse 
brains and grown as xenografts [114].    
A second limitation of in vitro cultures is that neurosphere cultures are established 
cell lines, even if they are established from primary tumor specimens.  When establishing 
a primary cell line, the majority of cells contained within the primary tissue sample do 
not survive, enriching for only a small fraction of cells.  The clonal frequency of cells 
derived from primary glioblastoma specimens is between 0.5 and 31% [42].  This small 
fraction of cells is thought to be the self-renewing stem cell population.  Various types of 
cells such as endothelial cells or blood cells that contribute to the in vivo niche likely do 
not survive under these conditions.  Only 50% of primary GBM specimens that formed 
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clonal colonies in vitro could develop into an established, steadily expanding, stable cell 
lines [42], indicating that an in vivo niche may in fact be critical in maintaining GBM 
stem/progenitor cells in some tumors. 
In addition to the in vitro environment being so different from the in vivo 
environment, cells maintained in long-term cultures can accumulate mutations with time.  
The genetic profiles of primary malignant GBMs, primary malignant GBM cultures 
grown as adherent cells in FBS, and primary malignant GBM cultures grown on agar as 
spheroids were analyzed by comparative genomic hybridization.  Malignant GBM 
cultures grown as adherent cells were only 62% genetically similar to the primary tissue 
from which they were derived.  GBM cells grown as spheroids were 89% genetically 
similar to the primary tissue, indicating that spheroid cultures do undergo some genetic 
changes, but are more representative of the primary glioblastoma compared with adherent 
cultures [116]. 
 Despite the fact that there are limitations to our culture system, we still believe 
that our in vitro experiments and results help predict the efficacy of chemotherapy 
treatments in vivo.  Based on our results, we see that neurosphere formation in vitro is 
inhibited by chemotherapy.  Following chemotherapy treatment, GBM growth is also 
inhibited resulting in tumor remission [117].  Neurosphere cultures that show recovery of 
neurosphere formation following a recovery period also show significant secondary 
sphere formation, indicating that NICs remained viable and could repopulate neurosphere 
cultures following chemotherapy treatment in vitro.  Tumor recurrence in GBM patients 
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confirms that a fraction of cells remains viable and capable of regrowing a tumor 
following chemotherapy treatment in vivo [15].  Chemotherapy-treated neurospheres that 
recover following treatment are capable of forming tumors in mice, confirming in vivo 
that GBM cells cultured as neurospheres and treated in vitro remained viable and 
tumorigenic.  These results indicate that our in vitro experimental system replicates how 
cells respond to chemotherapy in vivo.    
DNA damage and G2 cell cycle checkpoints 
Based on our Comet assay data from PET2 cells, we can make a couple of 
conclusions.  PET2 cells accumulate breaks in DNA following chemotherapy treatment, 
indicating that these GBM-like cells are not resistant to accumulating DNA damage.  
Based on recovery experiments, we can also conclude that some PET2 cells are resistant 
to DNA damage-induced cell death.  The DNA damage response involves several 
pathways, including DNA repair, cell cycle checkpoint arrest, and apoptosis.  Cell cycle 
checkpoints are critical for monitoring genomic integrity and stability.  In the presence of 
DNA damage, cell cycle arrest can provide time for DNA repair.  If DNA is damaged 
beyond repair, cells may enter the senescence or apoptosis pathway [118, 119].  Some 
GBM neurosphere cultures, such as PET2, undergo reversible cell cycle arrest, which 
may be one mechanism of chemoresistance. In addition, PET2 cells express mutant p53, 
which makes cells more resistant to apoptosis and hence may also be contributing to 
PET2 survival. 
Mismatch Repair, the MRN complex, and p38 
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 The MRN complex containing the proteins Mre11, Rad50, and Nbs1 plays an 
important role in the early activation of the DNA damage response, and possibly a role in 
maintaining G2 arrest.  The MRN protein complex has been shown to be one of the 
earliest sensors of TMZ-induced DNA damage.  MRN is activated in response to TMZ-
induced O6-meG lesions that form within minutes of drug exposure rather than the TMZ-
induced DNA single and double strand breaks that form 24-72 hours after TMZ exposure.  
Specifically, MRN complex foci formation is driven by the activation of the mismatch 
repair system in response to O6-meG mismatches.  MRN mediates activation of ATM, 
which targets Chk1 and Chk2.  The MRN complex therefore is thought to be an early 
sensor for double strand breaks, as well as being an activator of kinases required for cell 
cycle arrest.  Cells with functional MRN and mismatch repair can undergo prolonged 
arrest in the G2 phase of the cell cycle in response to TMZ-induced lesions.  Suppression 
of Mre11, a component of the MRN complex, did not prevent MGMT deficient U87 cells 
from undergoing G2 arrest, but did significantly reduce the ability of these cells to 
maintain G2 cell cycle arrest, and increased cell survival [120].  These results indicate 
that prolonged G2 arrest may be detrimental to cells with functional MRN complex and 
MMR pathways.   
 p38 is a stress activated mitogen-activated protein kinase (MAPK) that can also 
be involved in the induction of the G2/M checkpoint following DNA damage [121].  
Similar to the MRN complex, p38 is activated in response to MMR processing of TMZ-
induced O6-meG lesions in MMR-proficient cells.  Following DNA damage-induced 
activation, p38 activates the G2 cell cycle checkpoint.  In one study, selective inhibitors 
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of p38 dramatically inhibited the ability of U87 cells to undergo G2 cell cycle arrest 
following TMZ treatment.  In this study, TMZ-induced G2 cell cycle arrest mediated by 
p38 was dependent on phosphorylation of Cdc25 and Cdc2, and independent of Chk1 or 
Chk2 phosphorylation.  TMZ treated cells in which p38 function was inhibited had 
reduced colony formation efficiency, and showed an increase in the percent of β-
galactosidase positive senescent cells and cells with abnormal nuclei.  Cells with 
functional p38 on the other hand avoid senescence and premature entrance into mitosis 
by maintaining prolonged G2 arrest, indicating that p38 may be involved in allowing 
cells with damaged DNA to survive mitosis [122].  p38 MAPK-mediated G2 cell cycle 
arrest following chemotherapy treatment may be a mechanism of chemoresistance in 
some cells.     
ATM/ATR/AKT/p53/Chk1/2 
 Treatment with TMZ can inhibit cell growth and induce G2/M cell cycle arrest in 
MMR proficient cells via several pathways.  Growth and cell cycle arrest induced by 
TMZ treatment is associated with activation of ATM and ATR kinases.  Although ATM 
is activated, it is not required for G2 arrest.  ATM and ATR phophorylate p53, Chk1, and 
Chk2.  Chk1 and Chk2 can also phosphorylate p53, Cdc25A, and Cdc25C resulting in G2 
cell cycle arrest [123].  Cells expressing wild-type p53 predominantly arrest in G1 phase, 
whereas cells expressing mutant p53 bypass the G1 checkpoint and arrest in S or G2 
phase [124, 125].  Cdc25B has also been shown to be upregulated following DNA 
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damage.  This increase in Cdc25B expression is associated with recovery from G2/M cell 
cycle arrest [111].   
PET2 and U373NS cultures both had significant recovery of neurosphere 
formation following chemotherapy treatment, and both underwent reversible G2/M or S 
phase arrest.  Both PET2 and U373NS cells express a mutant form of p53.  Mutations in 
p53 can make cells resistant to earlier cell cycle checkpoints [124, 125], which might 
explain why PET2 and U373NS cultures arrest in G2/M or S phase.  This cell cycle arrest 
may have provided time for DNA repair and hence made cells resistant to apoptosis and 
mitotic catastrophe. 
Chk1/Chk2 Inhibition 
 Chk1 and Chk2 are activated in response to DNA damage.  Whereas Chk2 
activation is associated more with IR induced DNA damage, Chk1 activation is primarily 
initiated by DNA-replication blocking agents, such as UV or chemotherapy treatment 
[125, 126].  Chk1 is phosphorylated in response to DNA damage, and remains 
phosphorylated during the repair of double strand breaks [127].  Deficiency of Chk1 in 
ES cells results in severe defects in proliferation, and a defective G2/M DNA damage 
checkpoint, indicating that Chk1 is important in maintaining DNA damage checkpoints 
[128].  Compared with normal cells, cancer cells, especially those that express defective 
p53, more frequently bypass the G1 checkpoint and rely more on G2 arrest to protect 
against DNA damage [125].  In cells with non-functional p53, G2 arrest is dependent on 
Chk1.  Chk1-dependent G2 arrest also protects cells from oxidative stress [127].  
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Abrogating the G2 cell cycle checkpoint forces cells to divide with unrepaired DNA, 
which can result in enhanced cell death.  Inhibiting G2 cell cycle arrest by inhibiting 
Chk1 is one approach researchers are using to enhance current cancer therapies [125, 
129, 130].   
Abrogating cell cycle checkpoints by inhibiting Chk1/2 has been proposed in 
previous studies as one approach to enhancing standard GBM therapies [79].  In a study 
using CD133+ neurosphere initiating cells, IR resulted in an increase in the CD133+ 
neurosphere initiating fraction, and induced the upregulation of several DNA damage 
checkpoint genes including Chk1/2.  Combined IR and treatment with the Chk1/2 
inhibitor DBH prevented neurosphere formation, indicating that this combined treatment 
was chemotoxic to NICs [79]. DBH is a specific and potent inhibitor of Chk1/2, but not 
ATM or ATR [131]. 
Inhibition of Chk1/2 using the compound UCN-01 results in reduced inhibition of 
Cdc25B, which is associated with recovery from G2/M arrest.  UCN-01 induced exit 
from cell cycle arrest in chemotherapy treated AML cells, which resulted in enhanced 
cytotoxicity [111].  UCN-01 abrogates DNA damage induced G2 and/or S phase arrest 
and sensitizes human colon cancer cells to DNA damaging agents, most selectively in 
p53 deficient cells [125, 132].  Another compound with structural similarities to UCN-01 
used to inhibit Chk1 is isogranulatimide (ISO).  Although structurally similar, ISO is a 
more potent inhibitor of Chk1 than Chk2 [133].    
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Based on these previous studies, we decided to treat GBM neurosphere cultures 
that underwent reversible cell cycle arrest with a combination of chemotherapy and Chk1 
or Chk1/2 inhibitor to see if we could enhance cyotoxicity.  Combined treatment of 
PET2NS and U373NS cultures with chemotherapy drug and the Chk1 inhibitor ISO 
(Figure 2.22) or the Chk1/Chk2 inhibitor DBH (Figure 2.23) did not significantly inhibit 
neurosphere formation, or recovery of neurosphere formation following treatment.  These 
results imply that avoiding chemotoxicity is not dependent on Chk1/2 mediated G2/M 
arrest. 
Chemoresistance 
Some GBM cell lines do not arrest and/or do not contain populations of NICs that 
recovery following chemotherapy treatment, but do contain NICs capable of secondary 
sphere formation.  These results indicate that some GBM NICs are chemoresistant.  Some 
of these NICs that continue to proliferate in the presence of chemotherapy may be 
accumulating toxic DNA damage and will probably undergo mitotic catastrophe.  
Secondary sphere formation shows that a fraction of NICs have still remained viable 
during chemotherapy treatment, and that these NICs can restore the neurosphere culture 
if given time.  These NICs may maintain quiescent G0 arrest, may have an upregulated 
DNA repair response, or may be more resistant to apoptosis. 
Many mechanisms likely contribute to GBM cell survival.  MGMT is a methyl 
transferase that can repair chemotherapy-induced lesions.  MGMT is a “suicide” repair 
protein that can become saturated with continuous drug exposure, which is generally how 
chemotherapy is administered: for several sequential days.  So, even cells expressing 
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MGMT can accumulate toxic DNA damage.  The majority of our cultures do not express 
MGMT, so chemoresistance is likely due to another mechanism.   
Mutations in the oncogene p53 may also contribute to chemoresistance.  Several 
of our cultures express a mutant form of p53.  Cells that express a mutant form of p53 
have higher numbers of proliferating NICs [75], and are more resistant to apoptosis [75, 
134].  Cancer development is sometimes associated with p53 inactivation and decreased 
apoptosis [76].  In cells with wild-type p53, apoptosis triggered by TMZ-induced DNA 
breaks involves the Fas/CD95/Apo-1 receptor pathway.  In cells with mutant p53, 
apoptosis triggered by TMZ-induced DNA breaks involves the less efficient 
mitochondrial apoptotic pathway [17].  Inhibition of p53 enhances clonogenic survival, 
whereas rescuing p53 function in cells with mutant p53 causes cells to become more 
chemosensitive [135].  Expressing a mutant form of p53 enhances cell survival and 
decreases apoptosis in response to chemotherapy. 
Clinical studies determining the prognostic value of p53 mutations in the response 
of GBMs to chemotherapy are somewhat controversial.  Mutations in p53 are associated 
with resistance to several different chemotherapeutic agents in several cancers such as 
breast, rectal, colorectal, and ovarian [136].  A study analyzing 32 GBM patients 
concluded that p53 status had no prognostic value in determining patient survival [137].  
Another study analyzing 301 GBM patients also concluded that p53 status was not 
significantly associated with median progression-free or overall survival [138].  Contrary 
to these reports, yet another study analyzing 114 GBMs found that patients that had 
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detectable levels of p53 have significantly better overall survival [139].  Gene transfer of 
wild-type p53 into cells with mutant p53 sensitized GBM cells to chemotherapy and 
radiation [140].  Overall, these results indicate that GBMs with mutations in p53 might be 
more resistant to therapy compared with cells expressing wild-type p53. 
Many mechanisms likely contribute to GBM chemoresistance, and these 
mechanisms are likely different from patient to patient depending on the patient‟s specific 
genetic and/or chromosomal aberrations.  Even within individual GBM neurosphere 
cultures, I believe chemotherapy treatment results in a complex heterogeneity of cells.  A 
fraction of cells likely undergoes mitotic catastrophe.  Cells that accumulate extensive 
DNA damage but do not undergo mitotic catastrophe likely become senescent.  In some 
GBM cultures, a fraction of cells appears to undergo reversible cell cycle arrest.  In some 
GBM cultures, there is likely a fraction of quiescent cells as well.  We believe that the 
chemoresistant, reversibly arrested, and quiescent chemotherapy-treated GBM cells are 
representative of the GBM cells responsible for tumor regrowth in vivo.  Due to the 
complex heterogeneity of cells that arises following chemotherapy treatment, successful 
treatments will have to include a patient specifically designed treatment protocol 
including chemotherapy and additional drugs to target patient-specific mechanisms of 
chemoresistance. 
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Future Directions 
We believe that our experimental system allows us to replicate in vitro how GBM 
cells respond “long-term” to chemotherapy treatment in vivo.  Following surgical 
resection, GBM tissue can be used to establish patient specific primary GBM 
neurosphere cultures.  Using our experimental system, we can treat patient specific 
cultures with various chemotherapy drugs and treatment regiments and look at 
neurosphere formation after chemotherapy treatment, after a recovery period following 
chemotherapy treatment, and after trituration of recovered cultures and an extended 
recovery period.  Within weeks, researchers can determine what drug treatment and 
regiment is most effective in preventing neurosphere formation and recovery.  Using this 
data, we can then predict what drug treatment would be most efficacious for treating a 
patient‟s GBM and preventing recurrence in vivo. 
Results shown and discussed in this thesis indicate that GBMs are heterogenous, and that 
GBM cultures grown in vitro respond differently to chemotherapy.  Within individual 
GBM cultures, we see a heterogenous mix of cells including fractions of chemoresistant 
and/or reversibly arrested cells.  Although some GBM cultures do not survive 
chemotherapy treatment, several do.  Survival and recovery of these cultures indicates 
that additional drug treatments may be required to effectively kill off GBM cells (Figure 
2.24). 
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Figure 2.24:  Future approaches to enhancing chemotherapy may require a combination 
of drugs administered in a particular dosing schedule.  A) We found that following TMZ 
or BCNU treatment, neurosphere cultures contain a fraction of quiescent and/or 
mitotically arrested cells.  B) In order to kill arrested GBM cells, chemotherapy 
treatments may required a combination of drugs. C) GBMs also contain fractions of 
chemoresistant cells that may be more susceptible to cell death if a combination of drugs 
is used. 
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Several pathways are activated in response to DNA damage.  Cell cycle arrest is 
one response, and can prevent cells from accumulating additional DNA damage, and can 
provide time for DNA repair [118, 119].  We propose that cell cycle arrest may be 
contributing to GBM cell survival following chemotherapy treatment.       
p38 is a kinase that is activated in response to processing O6-meG lesions induced 
by TMZ, and is also involved in inducing G2/M checkpoints following DNA damage 
[121].  Inhibition of p38 in addition to TMZ treatment inhibited cells from undergoing 
G2 arrest, reduced colony formation efficiency, and increased the percent of senescent 
cells and cells with abnormal nuclei [122].  This approach may have been effective at 
preventing recovery and survival in our cell lines as well.  Several p38 inhibitors are in 
phase II clinical trials [141].  Treating patients with a combination of chemotherapy and 
p38 inhibitors may enhance the induction of senescence or cell death for some GBMs. 
One approach we tried using to enhance TMZ treatment was the addition of 
Chk1/2 inhibitors.  Chk1 is phosphorylated in response to DNA damage [127], and is 
important in maintaining DNA damage-induced cell cycle checkpoints [128].  p53 mutant 
cells need Chk1 to arrest in G2 [127].  Inhibiting G2 cell cycle arrest by inhibiting Chk1 
can enhance cell death and is one approach that has been used to enhance current cancer 
therapies [125, 129, 130].  Although our results indicate that inhibiting Chk1/2 does not 
enhance chemotoxicity, we may have obtained different results with a different dosing 
schedule.  For example, TMZ-induced DNA single and double strand breaks take 24-72 
hours to form after exposure to drug.  Apoptosis trigged by TMZ-induced double strand 
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breaks doesn‟t occur until at least four days after treatment [17].  Chk1 is phosphorylated 
in response to DNA damage [127], prior to the induction of cell cycle arrest.  Results here 
were obtained from experiments in which TMZ and Chk1 or Chk1/2 inhibitor were added 
concomitantly.  Inhibition of Chk may have been more effective if inhibitors were 
administered 24 hours or more after chemotherapy treatment, which is when Chk1/2 are 
activated.   
Experiments by Gilbert et al. show that the dosing schedule is critical when 
combining chemotherapy with another drug treatment.  TMZ treatment induced a fraction 
of cells to become senescent, based on β-galactosidase staining.  When the γ-secretase 
inhibitor DAPT was added 24 hours after TMZ, the percent of senescent cells in the 
culture doubled.  Combined TMZ followed by DAPT treatment prevented recovery of 
neurosphere formation, as well as secondary sphere formation, indicating that this 
combined treatment was effective at preventing recovery of neurosphere cultures after 
chemotherapy treatment alone.  These results were not obtained when TMZ and DAPT 
were added concomitantly, indicating that a specific dosing schedule is required to be 
effective when combining drug treatments [142]. 
p53 likely contributes to chemoresistance by making cells more resistant to 
apoptosis, and by contributing to cell cycle arrest.  Another possible approach for future 
therapy might be the reintroduction of wt-p53 into cells that express mutant p53.  Wt-p53 
can be introduced into cells [143], which may make them more sensitive to the toxic 
effects of chemotherapy. 
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Although cell cycle arrest may be one mechanism contributing to GBM cell 
survival following chemotherapy treatment, cell-cell contact of GBM or neurosphere 
cells derived from GBMs may also be contributing to chemoresistance and/or survival of 
GBM cells. We saw that when chemotherapy drugs were added to single cell 
suspensions, neurosphere formation was inhibited at fairly low doses of drug (Figure 
2.9).  If chemotherapy drugs were added to neurospheres, the neurospheres would 
continue growing.  This observation indicates that cell-cell adhesion may contribute to 
chemoresistance.  This might also explain why chemotherapy is effective following 
surgical resection where the remaining cells have been separated from the main tumor 
mass. 
Overall, the results presented in this thesis and in many other studies indicate that 
current treatments are not effective in curing GBM patients.  Based on the heterogeneity 
of GBMs, future therapies should be patient-specific, and may require a combination of 
several different drugs and dosing schedules.  Hopefully, our in vitro studies and 
experimental system can contribute to the design of successful patient-specific therapies. 
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Appendix 1: 
Determining the role of embryonic specific microRNAs in the 
differentiation of neural precursors from murine embryonic stem cells 
 
Summary 
MicroRNA (miRNA) expression changes during brain development.  We had 
hypothesized that expression levels of specific miRNAs change during the differentiation 
of murine embryonic stem cells (mESCs) to neural precursors, and that miRNAs are 
involved in regulating either maintenance of stem-cell properties, or early neuronal 
differentiation.  We had proposed to identify miRNAs and corresponding target genes 
that are required for proper differentiation of mESCs to neural precursors. 
 
Introduction 
Discovery of Gene Regulation by miRNAs 
miRNAs are a class of short RNA molecules that participate in gene regulation 
known as RNA interference (RNAi).  They are generated from primary RNA transcripts 
(pri-miRNAs) that range from several hundred to several thousand bases in length.  Pri-
miRNAs are cleaved in the nucleus by the RNase III nuclease Drosha into short hairpin 
structures of approximately 70 nts.  Short hairpin precursors are called pre-miRNAs.  
Characteristic of all RNase III cleavage products, pre-miRNAs have 3‟ 2 nt overhangs.  
Following export into the cytoplasm mediated by Exportin-5, pre-miRNAs are then 
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cleaved by the RNase III nuclease Dicer into approximately ~22 nt mature miRNA 
duplexes [144, 145].  While a miRNA:miRNA* duplex is generated from each pre-
miRNA, miRNA* sequences are detected at a much lower frequency in cDNA libraries 
[146, 147].  miRNA:miRNA* duplexes are separated by helicases.  miRNAs then bind 
the 3‟ UTR of target mRNAs, inhibiting gene expression post-transcriptionally [148].  
See Figure A.1. 
Many miRNAs are expressed in specific tissues or cell-types, and that expression 
of specific miRNAs often changes during development.  The tissue and cell-specificity of 
miRNA expression suggests that miRNAs are involved in cell fate determination.  In fact, 
inhibition of the miRNA miR-143 inhibited adipocyte differentiation in human pre-
adipocytes, leading to the conclusion that miR-143 regulates adipocyte differentiation 
[149].  miR-181 was found to promote B-cell differentiation from hematopoietic 
progenitor cells [150, 151].  Since we terminated this study, several microRNAs have 
been identified as regulators of neurogenesis in embryonic and adult brain [152].    
One of the first studied miRNAs let-7 controls developmental timing in C. 
elegans.  let-7 is complementary to sequences in the 3‟ untranslated region (UTR) of 
several genes [153].  Similar to let-7, some mammalian miRNAs, such as miR-1 and 
miR-124, are capable of downregulating multiple target genes [146, 154].  Analysis of 
human, mouse, rat, and dog genomes identified several common regulatory motifs in 
promoters and 3‟UTRs of genes.  Based on miRNA sequence complementarity to these 
regulatory motifs, authors predicted that several mammalian miRNAs are capable of  
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Figure A.1:  miRNAs are critical regulators of gene expression.  A)  Pri-miRNAs are 
transcribed and cleaved in the nucleus into short hairpin structures called pre-miRNAs.  
B)  Following export into the cytoplasm, pre-miRNAs are then cleaved into 
approximately ~22 nt mature miRNA:miRNA* duplexes, which are separated by 
helicases.  C)  miRNAs then bind the 3‟ UTR of target mRNAs, inhibiting gene 
expression post-transcriptionally by inhibiting mRNA translation. 
Modified from [155, 156]. 
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binding multiple target genes [157].  In addition to miRNAs being capable of binding 
multiple targets, some target genes also contain multiple miRNA binding sites for either 
the same miRNA or for multiple miRNAs, indicating a very complex regulatory network 
mediated by miRNAs [158].   
 Mammalian ESCs express miRNAs that are down-regulated upon differentiation 
into embroid bodies (EBs).  These miRNAs are not expressed in adult tissues.  The ESC 
specificity of these miRNAs suggested that they are involved in early mammalian 
development [159].  The ESC-associated miRNAs identified in Houbaviy, et al are also 
conserved in human ESCs [160].  Their conservation indicates that these miRNAs are 
biologically important.    Interestingly, Dicer deficiency, and hence the inability of cells 
to produce mature miRNAs, is embryonic lethal [161].  Specifically, Dicer null ESCs are 
not capable of differentiating into the three germ layers [162].  These results demonstrate 
that RNAi is in fact required for early differentiation and development of murine ESCs.   
Similar to ESCs, analysis of miRNA expression in brain tissue has identified 
several miRNAs specific to differentiating brain [163, 164].  Specifically, the analysis of 
miRNA expression in developing brain tissue shows that the expression pattern of several 
miRNAs changes during brain development, with groups of some miRNAs decreasing, 
and some increasing [163, 165].  Much progress has been made in understanding of the 
role miRNAs play in brain development [152, 166].  Based on the specific expression 
pattern of miRNAs in the developing brain, and the known roles of several miRNAs in 
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the early development of multiple organisms, we had hypothesized that miRNAs are 
involved in the regulation of early neural development. 
The changes in expression levels of mESC specific miRNAs during early neural 
development can be examined by differentiating mESCs with Retinoic Acid (RA).  
mESCs treated with RA differentiate into neuron-like cells that express a variety of 
neural genes including Wnt-1, which is expressed during neural tube development, and 
MASH1, which is expressed in neuronal precursors but not mature neurons [167].   
If a miRNA is upregulated upon early differentiation, it may be involved in 
silencing genes involved in maintaining pluripotency and sustained self-renewal.  
Inhibiting a miRNA involved in maintaining stem cell-like properties should induce 
differentiation and/or inhibition cell proliferation.  If a miRNA is downregulated upon 
early differentiation, it may also be involved in suppressing genes involved in early 
differentiation.  Inhibiting a miRNA involved in suppressing differentiation should 
induce differentiation. 
The function of a miRNA can be studied by inhibiting the miRNA with antisense 
oligonucleotides called antagomirs [156, 168, 169].  Oligonucleotides with sequences 
complimentary to an exogenous siRNA or endogenous miRNA and a 2‟O-methyl 
overhang for stability can be synthesized and used as potent, irreversible, and 
stoichiometric inhibitors of siRNA or miRNA function [156].  2‟O-methyl-
oligonucleotide binding to a siRNA or miRNA prevents the the siRNA or miRNA from 
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binding to its target gene, and hence prevents the inhibition of that target gene (Figure 
A.2). 
To validate whether 2‟O-methyl oligonucleotides were efficiently inhibiting gene 
expression, we set up an experimental system in HeLa cells using luciferase-expressing 
target constructs, exogenous miRNA mimics, and 2‟O-methyl oligonucleotide inhibitors.  
In HeLa cells, luciferase expression from miR290-295 target constructs could be 
inhibited with exogenous miRNA duplexes.  When transfected with inhibitory 2‟O-
methyl oligonucleotides, target luciferase expression was not inhibited by exogenous 
miRNA duplexes in HeLa cells, indicating that antisense oligonucleotide inhibition was 
successful in inhibiting miRNA inhibition of luciferase expression from target constructs.  
When electroporated into mESCs, luciferase expression from miR290-295 target 
constructs was inhibited with endogenous miRNA duplexes.  Unfortunately, inhibition of 
luciferase by endogenous miRNAs was not inhibited when co-electroporated with 2‟O-
methyl oligonucleotide inhibitors for the majority of the luciferase target genes.  2‟O-
methyl oligonucleotide inhibition was only partially effective at inhibiting miR290 
inhibition of target luciferase gene expression.  Inhibition of miR290 with 2‟O-methyl 
oligonucleotide inhibitor did not induce any obvious phenotypic change in mESCs or 
mESCs inducted to differentiate into EBs.  
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Figure A.2:  Schematic of luciferase assays.  A)  miRNA recognition elements were 
cloned into the luciferase expressing vector PRL-TK.  B)  When electroporated into 
mESCs, endogenous miRNAs in mESCs or C) transfected exogenous miRNAs in HeLa 
cells will inhibit luciferase expression.  D)  Inhibitory 2‟O-methyl oligonucleotides 
complimentary to the miRNA of interest will bind to miRNAs, preventing miRNAs from 
repressing target gene expression, or in this case, luciferase target expression. 
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Materials and Methods 
Cell Culture 
HeLa cells were cultured in DMEM with 10% FCS.  AB2.2 mESCs were grown 
on inactivated SNL76 murine embryonic fibroblast (MEF) feeder cells, and maintained in 
DMEM with 15% FCS tested for ES maintenance (Hyclone), 1 mM -mercaptoethanol, 
2mM L-glutamine, 1mM penicillin/streptomycin. 
SNL76 MEF cells express leukemia inhibitory factor (LIF), which is required for 
mESC growth and maintenance.  Feeder cells are inactivated by treatment with 10mg/ml 
of Mitomycin C (Roche) to prevent them from outgrowing mESCs.  Feeder cells are 
grown on gelatin-coated plates in DMEM, 7% FCS, and 1mM penicillin/streptomycin.   
Early mESC Differentiation 
mESCs were differentiated into embroid bodies (EBs) using a couple of different 
protocols.  First, mESCs were grown on gelatin-coated plates in LIF-free media for four 
or fourteen days.  Second, mESCs were grown in bacterial dishes without LIF for four or 
eight days.  In addition to growing mESCs in bactertial dishes without LIF, some cells 
were treated with 0.5 µM retinoic acid (RA) to induce neural differentiation [167]. 
Northern Blotting 
 Northern blotting was used to assess levels of mESC specific miRNA levels in 
mESCs and slightly differentiated EBs.  RNA was isolated from mESCs, MEFs, and EBs 
using TRI Reagent-LS (Molecular Research Center, Inc, Cincinnati, OH), followed by 
ethanol precipitation.  RNA was denatured by boiling for two minutes in formamide 
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loading buffer (98% v/v deionized formamide, 10 mM EDTA, 0.025% w/v xylene 
cyanol, and 0.025% w/v bromophenol blue) prior to loading and running on a 15% 
denaturing polyacrylamide gel (National Diagnostics SequaGel Sequencing System, 
Atlanta, GA).  RNA was transferred to a N+ Hybond membrane (GE LifeSciences, 
Piscataway, NJ) using a semi-dry transfer apparatus, and crosslinked to the membrane 
using UV.  miRNAs of interest (sequences are listed in [159]) were probed with γ32P-
radiolabeled anti-sense miRNAs complementary to our miRNAs of interest (Dharmacon, 
Lafayette, CO), and detected using a FLA-5000 phosphoimager (Fuji).  miRNA intensity 
was quantified using Image Reader FLA-5000 version 1.0 and Image Gauge version 3.45 
(Fuji).   
Cloning miRNA Target constructs  
 To experimentally validate miRNA target gene inhibition, we created Luciferase 
expressing plasmids with miRNA binding sites.  One and four miRNA binding sites, or 
recognition elements, were cloned into the 3‟UTR of a pRL-TK luciferase vector 
(Promega, Madison, WI) for all six miRNAs and their anti-sense sequences.  Specifically, 
oligonucleotides with sequences complimentary to our miRNAs of interest and their 
antisense sequences were ordered from Dharmacon with Xba and Not1 restriction site 
overhangs.  Prior to cloning into pRL-TK plasmids, oligonucleotide pairs, or 
miRNA:miRNA* mimics, were annealed at room temperature for one hour in Tris-
EDTA.  Target pRL-TK luciferase plasmids were cut with Xba and Not1 (NEB, Ipswich, 
MA) and agarose gel purified prior to ligation with annealed miRNA binding sequences 
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or recognition elements using T4 ligase (Invitrogen) in provided ligation buffer overnight 
at 16ºC.  
Transfection, Electroportation, and Luciferase assays 
To confirm functional luciferase expression from these cloned constructs, HeLa 
cells were transfected using Lipofectamine 2000 (Invitrogen) using protocols provided 
with pRL-TK plasmids containing the miRNA recognition elements, as well as PGL2 
luciferase plasmids (Promega) for use as an internal control for experimental variations.  
Introduction of DNA into mESCs was most efficient when mESCs were electroporated 
with plasmids previously incubated with Lipofectamine 2000.  Specifically, mESCs were 
electroporated in 1 ml of OptiMEM (Invitrogen) in a 0.4 cm cuvette using a Bio-Rad 
electroporator set to 300 V and 900 µF. 
Levels of luciferase expression were assayed using Dual-Luciferase Reporter 
Assay Stop and Glo substrates (Promega) and a Mediators PhL luminometer (ImmTech 
Incorporated) 24 hours after transfection or electroporation.  Values for luciferase activity 
were calculated by dividing target pRL-TK luciferase values by control PGL2 luciferase 
values to normalize between readings.  The optimal concentrations of target pRL-TK 
construct were determined by comparing target luciferase expression to control PGL2 
luciferase expression in HeLa cells.  Experiments were repeated until equal expression 
levels of luciferase were obtained for both control and target contructs.   
Inhibition of miRNA function using sequence specific inhibitors 
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In some cases, 2‟-O-methyl olignonucleotides complimentary to a miRNA can be 
irreversible inhibitors of miRNA function [156].  To examine inhibition of miRNA 
function using complementary 2‟-O-methyl or 2‟cholesterol-O-methyl oligonucleotides 
(Dharmacon), both target pRL-TK and control PGL2 luciferase plasmids, exogenous 
miRNA duplexes, and inhibitory oligonucleotides were transfected into HeLa cells 
followed by luciferase assay.  To examine inhibition of endogenous miRNAs in mESCs, 
mESCs were electroporated with luciferase plasmids and inhibitory oligonucleotides 
(Figure A.2). 
Assessing the proliferation and differentiation of mESC and EB cultures following 
inhibition of miR290 
Proliferation of mESCs or EBs electroporated with 2‟O-Me‟s against miR290 or 
against target non-specific and non-inhibitory (miR292) control 2‟O-Me‟s was assessed 
by MTT Assay.  Treated cultures were triturated break up ES or EB colonies, and viable 
cells were measured using 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) reagent according to  manufacturer‟s instructions (Promega Corp, 
Madison, WI) as mentioned in Materials and Methods in Chapter 2.   
A loss of AP staining is a measure of early differentiation.  mESCs or 
differentiated EBs electroporated with 2‟O-Me‟s against miR290 or miR292 2‟O-Me‟s 
were stained with alkaline phosphatase (AP) according to manufacturer‟s instructions 
(Chemicon/Millipore, Temecula, CA).  Briefly, mESCs were fixed with 4% 
paraformaldehyde for 1-2 minutes, rinsed with provided rinse buffer, and stained with 
98 
 
staining solution for AP activity.  Cells and/or neurospheres positive for AP became 
purple.  
 mESCs, 4 day EBs, 8 day EBs, and 8 day EBs treated with RA were assayed by 
RT-PCR for several stem and differentiation cell markers.  RNA was isolated using TRI 
Reagent-LS (Molecular Research Center, Inc, Cincinnati, OH), followed by ethanol 
precipitation according to manufacturer‟s protocol.  Briefly, cDNA was made using a 
SuperScript cDNA synthesis kit (Invitrogen).  cDNA (2 μl) was amplified with Platinum 
Taq DNA High Fidelity Polymerase (Invitrogen). The primers for amplification of: 
OCT4 cDNA (expressed in ESCs) were 5‟-GTTGGAGAAGGTGGAACCAACTC-3‟ 
and 5‟-CTTCAGCAGCTTGGCAAATG-3‟ [170]; Rex-1 cDNA (expressed in ESCs) 
were 5‟-AAAGTGAGATTAGCCCCGAG-3‟ and 5‟-TCCCATCCCCTTCAATAGCA-
3‟; Brachyury (expressed in mesoderm/primitive streak) were 5‟-
CATGTACTCTTTCTTGCTGG-3‟ and 5‟-GGTCTCGGGAAAGCAGTGGC-3‟ [171]; 
BMP4 cDNA (expressed in ectoderm/mesoderm) were 5‟-
TGTGAGGAGTTTCCATCACG-3‟ and 5‟-CAGCGAAGGACTGCAGGGCT [171]; 
HNF-4 cDNA (expressed in endoderm) were 5‟-CTTCCTTCTTCATGCCAG-3‟ and 5‟-
ACACGTCCCCATCTGAAG-3‟ [172]; Pax6 cDNA (expressed in neuroectoderm) were 
5‟-GCTTCATCCGAGTCTTCTCCGTTAG-3‟ and 5‟-
CCATCTTTGCTTGGGAAATCCG-3‟ [171]; FGF-5 cDNA (upregulated upon 
differentiation) were 5‟-GGCAGAAGTAGCGCGACGTT-3‟ and 5‟-
TCCGGTGCTCGGACTGCTT-3‟; and for HPRT (housekeeping control) were 5‟-
GCTGGTGAAAAGGACCTCT-3‟ and 5‟-CACAGGACTAGAACACCTGC-3‟ [173]. 
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Results 
Expression Levels of mESC specific miRNAs change upon differentiation 
 We analyzed the expression levels of mESC-specific miRNAs in mESCs, and 
mESCs that had been encouraged to form differentiated EBs.  Northern blotting of RNA 
isolated from mESCs, and EBs that had been grown on gelatin-coated plates in the 
absence of LIF for four or fourteen days indicated that miR292 was slightly upregulated 
at four, and even more so at fourteen days of growth without LIF.  Interestingly, the 
expression levels of miR290, miR291, miR292*, miR293, and miR294 increased after 
four days of growth without LIF, and then decreased after fourteen days of growth 
without LIF (Figure A.3A). 
 Northern blotting of RNA isolated from mESCs, and EBs that had been grown in 
bacterial plates in the absence of LIF with or without RA for four or eight days also 
showed changes in mESC specific miRNA expression levels.  Expression levels of 
miR291 increased with growth in the absence of LIF, and were even higher following 
treatment with RA.  Expression levels of miR290, miR292, miR292*, and miR293 were 
greater after eight days of growth without LIF compared with levels expressed in mESCs.  
Unlike miR291, expression levels of miR290, miR292, miR292*, and miR293 decreased  
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Figure A.3:  Expression levels of mES specific miRNA change upon differentiation.  A) 
miR292 was slightly upregulated at four and even more so at fourteen days of growth 
without LIF whereas the expression levels of miR290, miR291, miR292*, miR293, and 
miR294 increased after four days of growth without LIF, and then decreased after 
fourteen days of growth without LIF.  Expression levels of miR291 increased with 
growth in the absence of LIF, and were even higher following treatment with RA.  
Expression levels of miR290, miR292, miR292*, and miR293 were greater after eight 
days of growth without LIF compared with levels expressed in mESCs.  Unlike miR291, 
expression levels of miR290, miR292, miR292*, and miR293 decreased in RA-treated 
EBs compared with miRNA levels of eight day EBs not exposed to RA. 
101 
 
in RA-treated EBs compared with miRNA levels of eight day EBs not exposed to RA 
(Figure A.3B).   
miRNA target constructs express Luciferase which can be inhibited using miRNA 
duplexes 
 To measure miRNA target gene inhibition, we cloned miRNA binding sequences 
or recognition elements containing sequences complimentary to our miRNAs of interest 
into a luciferase expressing plasmid.  Specifically, miRNA binding sites were cloned into 
the 3‟UTR of a pRL-TK luciferase expressing plasmid.  At first, we were inserting only 
one miRNA binding site into the 3‟UTR of pRL-TK.  To enhance miRNA binding to 
target constructs, we cloned luciferase expressing plasmids containing four miRNA 
binding sites or recognition elements in the 3‟UTR of pRL-TK.  When transfected into 
HeLa cells, these miRNA target constructs expressed luciferase after 24 hours.  Since 
HeLa cells do not express mESC specific miRNAs, exogenous miRNA duplexes or 
mimics had to be introduced to inhibit luciferase target plasmid expression (Figure 
A.3C).  When transfected into HeLa cells along with luciferase target plasmids, 
exogenous miRNAs partially inhibited luciferase target gene expression.  Shown in 
Figure Figure A.4 is experimental data from luciferase assays in HeLa cells done using 
miRNA target constructs for miR290 (Figure A.4A) and miR294 (Figure A.4B), and 
inhibitory exogenous miRNA duplexes.  Data shown is representative of data obtained 
from luciferase assays done with the other miRNA target constructs.       
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Figure A.4:  In HeLa cells, miRNA target constructs express luciferase after 24 hours.   
When co-transfected with exogenous miRNA duplexes, target luciferase expression is 
inhibited.  When 2‟O-methyl oligonucleotides complimentary to miRNAs of interest 
were co-transfected with luciferase target plasmids and exogenous miRNA duplexes, 
miRNAs were inhibited resulting in target luciferase expression. Shown here is data 
obtained from experiments done with A) miR290 and B) miR294 target constructs, 
miRNA duplexes, and inhibitors.      
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In mESCs, luciferase target gene expression is inhibited by endogenous miRNAs.  
Shown in Figure A.5 is experimental data from luciferase assays in mESCs cells using 
target constructs for miR290 (Figure A.5A), and miR294 (Figure A.5B), which is 
representative of data obtained from luciferase assays done with the other miRNA target 
constructs.  The level of target luciferase inhibition in mESCs is determined by 
comparing to luciferase expression from a pRL-TK vector that does not have miRNA 
binding sites.   
Inhibition of target construct luciferase expression by miRNA mimics is blocked using 
2’O-methy oligonucleotides in HeLa cells 
After confirming inhibition of miRNA target construct luciferase expression using 
exogenous miRNA duplexes or mimics, we tested the efficacy of 2‟O-methyl 
oligonucleotides in blocking miRNA-mediated target inhibition in HeLa cells.  To 
determine if inhibitory 2‟O-Me oligonucleotides could block luciferase target inhibition, 
HeLa cells were electroporated with luciferase constructs, exogenous miRNA:miRNA* 
duplexes, and inhibitory 2‟O-Me oligonucleotides.  When target constructs were 
transfected with exogenous miRNA duplexes, target luciferase expression was inhibited.  
When target constructs were were electroporated with exogenous miRNA duplexes and 
inhibitory 2‟O-Me oligonucleotides, miRNA function was inhibited resulting in reduced 
inhibition of target construct luciferase expression (Figure A.4).  Functional target 
luciferase expression, inhibition by exogenous miRNA duplexes, and at least partial 
restoration of luciferase expression by 2‟O-methyl oligonucleotide inhibition was  
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Figure A.5:  In mESCs, miRNA target construct luciferase expression is inhibited by 
endogenous miRNA duplexes.  When 2‟O-methyl oligonucleotides complimentary to 
miRNAs of interest were co-electroporated with luciferase target plasmids, only 2‟O-
methyl oligonucleotides complimentary to miR290 were effective at partially preventing 
miRNA-mediated target luciferase expression.  Shown here is data obtained from 
experiments done with A) miR290 and B) miR294 target constructs and 2‟O-methyl 
oligonucleotide inhibitors.      
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confirmed for all target constructs made in HeLa cells. Data for experiments in HeLa 
cells done with miR290 and miR294 are shown in Figure A.4. 
2’O-methyl oligonucleotide inhibitors of endogenous miRNAs in mESCs were only 
effective for miR290 
To determine if inhibitory 2‟O-Me oligonucleotides could block luciferase target 
inhibition by endogenous miRNAs in mESCs, mESCs were electroporated with 
luciferase constructs and inhibitory 2‟O-Me oligonucleotides.  Unfortunately, 2‟O-Me 
oligonucleotide inhibition was only successful at partially preventing miRNA-mediated 
target luciferase inhibiton for miR290.  Shown in Figure A.5 is luciferase data from 
mESCs electroporated with miR290 target constructs with or without inhibitory 2‟O-Me 
oligonucleotides against miR290 or miR292-as as a non-functional target non-specific 
control.  miRNA target construct luciferase expression is inhibited by endogenous 
miRNAs.  When co-electroporated with 2‟O-Me oligonucleotides complimentary to 
miR290, target luciferase expression is partially restored (Figure A.5A).  When co-
electroporated with 2‟O-Me oligonucleotides complimentary to the other miRNAs, target 
luciferase constructs still express luciferase, indicating that 2‟O-Me oligonucleotides did 
not inhibit miRNA function for miR291-295.  Shown in Figure A.5B shows luciferase 
data from mESCs electroporated with miR294 target constructs with or without 
inhibitory 2‟O-Me oligonucleotides against miR294 or miR292 as a non-specific control, 
which is representative of data obtained for the other miRNAs studied.          
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Inhibition of miR290 using 2’O-methyl oligonucleotides did not induce any obvious 
phenotypic changes in mESCs 
 Electroporation of mESCs with 2‟O-methyl oligonucleotides against miR290 did 
not induce any obvious changes in mESC phenotype.  Data obtained from MTT assays 
indicated that the proliferative potential of cultures did not change with miR290 
inhibition (data not shown).  Specifically, mESCs electroporated with 2‟O-methyl 
oligonucleotides complimentary to miR290 showed equal proliferative protential 
compared with mESCs electroporated with 2‟O-methyl oligonucleotides complimentary 
to miR292.  In addition, partial inhibition of miR290 with inhibitory 2‟O-methyl 
oligonucleotides did not induce mESCs to differentiate, nor did miR290 inhibition 
prevent differentiation into EBs.  Specifically, mESCs did not lose AP staining, nor did 
EBs gain AP staining when electroporated with 2‟O-methyl oligonucleotides 
complimentary to miR290 (data not shown).  Based on RT-PCR, mir290 inhibition in 
mESCs or EBs induced no change in stem or differentiated cell marker expression (data 
not shown).  Overall, preliminary experiments indicated that inhibition of miR290 
function by 2‟O-methyl oligonucleotide inhibition induced no changes in mESC or mEB 
phenotype, proliferation potential, or maintenance of stem-like characteristics. 
 
Discussion 
 Shortly after the withdrawal of the growth factor LIF, which is required for the 
maintenance of stem cell-like self-renewal, the expression levels of several mESC-
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specific miRNAs increases, and then decreases by eight to fourteen days.  This 
upregulation of miRNAs implies that some miRNAs may be involved in the early 
differentiation of mESCs.  Several mESC specific miRNAs are also upregulated when 
RA acid is added to cells grown without LIF, which induces early neural differentiation.  
The upregulation of miRNAs with RA-induced neural precursor differentiation implies 
that some miRNAs expressed in mESCs may be involved in the early differentiation of 
mESCs to neural precursors.  Inhibition of these miRNAs should hence prevent 
differentiation.  The levels of other mESC specific miRNAs decreases with 
differentiation, indicating that these miRNAs are involved in maintaining stem-cell-like 
properties.  Inhibition of these miRNAs should induce differentiation. 
 Although successful at inhibiting miRNA function in HeLa cells, 2‟O-methyl 
oligonucleotide inhibitors were only successful at partially mediating miR290 inhibition 
of miR290 luciferase target plasmid luciferase expression in mESCs.  Results obtained 
from experiments done with luciferase target plasmids imply that 2‟O-methyl 
oligonucleotide inhibition is largely not effective in mESCs.  Attempts at inhibiting 
endogenous miR290 function in mESCs or in differentiated 4d EBs, or EBs treated with 
RA did not result in any obvious changes in cell phenotype or proliferation rates.  
Overall, inhibition of miR290 did not induce differentiation of mES cells, nor did it 
prevent differentiation in cells induced to differentiate. 
 Since the termination of this study, several groups have determined that antisense 
inhibition of individual or multiple mESC-specific miRNAs was not a successful 
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approach in producing a significant phenotype in mESCs or EBs.  Some miRNAs have 
redundant functions, and can be expressed at very high levels, making it difficult if not 
impossible to determine the function of individual mESC-specific miRNAs.   mESC-
specific miRNAs have since been determined to be essential for embryonic stem cell self-
renewal, and G1/S cell cycle progression.  Studies successfully elucidating the function 
of mESC-specific miRNAs have been done by re-introducing miRNAs into mESCs 
deficient in Dicer (Dgcr8-/-cells), which is required for miRNA biogenesis (Figure A.1) 
[174-177]. 
 Dgcr8-/- ESCs retain expression of self-renewal and pluripotency markers [174, 
177].   However, self-renewal is reduced in Dgcr8-/- ESCs due to accumulation of cells in 
the G1 phase of the cell cycle [175].  Dgcr8-/- ESCs express lower levels of de novo 
methyltransferases resulting in reduced de novo DNA methylation, and indicating that de 
novo DNA methylation in ES cells is controlled by miRNAs [178].  Introduction of 
miR294 restores self-renewal based on colony-formation in Dgcr8-/- ESCs [174].  
Introduction of miR291, miR292, and miR295 fully rescued G1 cell cycle accumulation 
in mESCs.  Expression levels of p21 are increased in Dgcr8-/- ESCs.  Experiments have 
shown that p21 is a target of mESC-specific miRNAs.  Other regulators of cell-cycle 
transitions are also likely targets of mESC-specific miRNAs [175, 176]. 
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